

Advances in biomarkers of benzene exposure and toxicity: From mechanistic insights to occupational health applications (Review)

YUANSHE HUANG¹, ZHENJUN XI², JINGXIN MAO² and XIAOBING LI²

¹College of Agriculture, AnShun University, Anshun, Guizhou 561000, P.R. China; ²Science and Technology Industry Development Center, Chongqing Medical and Pharmaceutical College, Chongqing 401331, P.R. China

Received July 6, 2026; Accepted August 12, 2026

DOI: 10.3892/mmr.2026.14028

Abstract. Benzene is a toxic aromatic hydrocarbon widely used in industrial production, posing a notable occupational health threat. Classified as a Group 1 carcinogen, chronic benzene exposure primarily targets the hematopoietic system, causing leukopenia, thrombocytopenia, aplastic anemia and acute myeloid leukemia. Furthermore, emerging evidence highlights its multi-systemic toxicity, inducing oxidative stress, DNA damage and cellular dysfunction, across the nervous, respiratory, dermatological, reproductive, immune and cardiovascular systems. The present review systematically summarizes recent advances in these occupational hazards and the evolving landscape of benzene biomonitoring. Traditional exposure biomarkers, such as urinary phenol and hydroquinone, are increasingly being supplemented by highly specific metabolites, notably S-phenylmercapturic acid, for low-dose exposure assessments. Effect biomarkers capture early biological damage through hematological indices and molecular alterations, while susceptibility biomarkers, such as cytochrome P450 2E1, glutathione S-transferase mu 1 and DNA repair gene polymorphisms, identify genetically vulnerable populations. Additionally, emerging non-invasive tools, particularly exhaled breath metabolomics, show promise in correlating specific metabolites with hematopoietic function. By integrating mechanistic insights into multi-organ toxicity with advanced multi-omics profiling, the present review highlights a critical paradigm shift from reactive traditional monitoring to artificial intelligence-driven, multi-biomarker integration frameworks. Ultimately, it provides a

forward-looking roadmap for individualized risk stratification and precision occupational health surveillance in the low-dose exposure era.

Contents

1. Introduction
2. Occupational hazards and systemic toxicity of benzene
3. Biomarkers of benzene
4. Integration of biomarkers into precision occupational health surveillance
5. Conclusion and future perspectives

1. Introduction

Benzene, a ubiquitous aromatic hydrocarbon, remains a cornerstone of the global petrochemical industry, widely employed in the synthesis of plastics, resins and synthetic fibers, as well as in solvents for paints, coatings and adhesives (1). However, its volatility and lipophilicity render it a pervasive occupational hazard. Despite stringent engineering controls, chronic exposure to benzene vapor persists in industries such as shoe manufacturing, chemical processing and fuel refining, posing a notable threat to global occupational health (2).

The hematotoxicity and leukemogenicity of benzene are well-established. Classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC), benzene is causally linked to aplastic anemia, myelodysplastic syndromes and acute myeloid leukemia (AML) (3-5). Beyond the hematopoietic system, emerging evidence indicates that benzene exerts systemic toxicity, inducing oxidative stress and functional impairment in the nervous, immune, reproductive and respiratory systems (6). The mechanism of toxicity is complex, primarily involving the hepatic metabolic activation of benzene by cytochrome P450 2E1 (CYP2E1) into reactive metabolites (such as benzoquinones and hydroquinones), which drive DNA damage, chromosomal aberrations and epigenetic dysregulation (7).

A notable challenge in current occupational health is the 'low-dose' paradox. While regulatory standards, such as China's occupational exposure limit (PC-TWA of 6 mg/m³)

Correspondence to: Dr Jingxin Mao or Dr Xiaobing Li, Science and Technology Industry Development Center, Chongqing Medical and Pharmaceutical College, 82 University Town Middle Road, Shapingba, Chongqing 401331, P.R. China
E-mail: 2230040@cqmpc.edu.cn
E-mail: xiaobing.li@cqmpc.edu.cn

Key words: benzene, occupational exposure, biomarkers, exposure biomarkers, effect biomarkers, susceptibility biomarkers, hematopoietic toxicity, exhaled breath metabolomics

and the American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit value (0.5 ppm), aim to protect workers, recent epidemiological studies reveal that hematotoxicity and genotoxicity occur at concentrations well below these permissible limits (8,9). This underscores a notable gap in the understanding of low-level exposure risks. Furthermore, conventional monitoring relies heavily on biomarkers such as trans,trans-muconic acid (tt-MA) or S-phenylmercapturic acid (SPMA). While superior to the historical marker urinary phenol, these indicators still face limitations in sensitivity and specificity when distinguishing low-dose occupational exposure from environmental background sources (for example smoking or traffic exhaust) (9).

Therefore, there is a need to elucidate the molecular mechanisms of benzene toxicity at low doses and to validate novel, non-invasive biomarkers for early effect monitoring (10). The present review synthesizes advances in domestic and international research, focusing on three key areas: i) The mechanistic basis of benzene-induced multi-organ toxicity, with a focus on oxidative stress and immune dysregulation; ii) the evolution of biomarkers, transitioning from traditional metabolites to emerging 'omics-based' markers (metabolomics, microRNA panels and DNA methylation); and iii) the clinical implications for precise risk assessment and health surveillance (11). By integrating these perspectives, the present review aimed to provide a theoretical foundation for updating occupational health standards and improving early intervention strategies (12). Consequently, integrating these multifaceted biomarkers into a cohesive framework utilizing artificial intelligence represents the next frontier in occupational medicine. The systematic literature search and study selection process for this review is detailed in Fig. 1.

2. Occupational hazards and systemic toxicity of benzene

Neurotoxicity and nervous system dysfunction. Benzene exerts cumulative neurotoxic effects involving both the central nervous system and peripheral nervous system (13). Chronic exposure induces a spectrum of neurobehavioral deficits—often termed 'chronic benzene encephalopathy', characterized by persistent cephalalgia, dizziness, insomnia and cognitive decline (14). These manifestations are underpinned by the disruption of neurotransmitter homeostasis. Mechanistic studies reveal that benzene metabolites inhibit tyrosine hydroxylase and other rate-limiting enzymes in dopamine and serotonin synthesis, thereby impairing synaptic transmission and neuronal signaling efficiency (15,16).

Neurobehavioral batteries corroborate these findings; for example, exposed workers demonstrate notably prolonged reaction times and a ~20% reduction in bilateral coordination scores compared with controls (17). Due to its high lipophilicity, benzene readily traverses the blood-brain barrier. Its accumulation, along with bioactive metabolites such as phenol, induces histopathological alterations in hippocampal neurons, including vacuolar degeneration and nuclear pyknosis (18). Furthermore, benzene compromises glial cell integrity, leading to myelin sheath instability and irregular Node of Ranvier spacing, which consequently reduces nerve conduction velocity (19). Peripheral neuropathy is equally prevalent (20). In a cohort of shoemaking workers, ~30% reported sensory

anomalies, including paresthesia and hypoesthesia (21). Electrophysiological assessments confirmed axonal damage, evidencing motor conduction velocities in median and ulnar nerves that were 3–5 m/sec slower than population norms (22). Notably, owing to the limited regenerative capacity of neural tissue, neurological deficits often persist irreversibly even after exposure cessation (23).

Hematotoxicity and malignancy risks. The hematopoietic system represents the primary target of benzene toxicity, displaying a dose-dependent vulnerability (24). Chronic exposure precipitates hematological dyscrasias ranging from leukopenia ($<3.5 \times 10^9/l$) and thrombocytopenia ($<100 \times 10^9/l$) to severe pancytopenia (25). In advanced stages, this progresses to aplastic anemia or hematologic malignancies (26). The mechanism is driven by hepatic metabolic activation via CYP2E1, generating reactive electrophiles (1,4-benzoquinone, hydroquinone) (27) (Fig. 2).

Due to their lipophilic nature and stability in circulation, these toxic intermediates are readily transported via the systemic bloodstream to the bone marrow microenvironment. Upon entering the hematopoietic niche, they induce severe oxidative stress, rapidly deplete intracellular glutathione reserves and form covalent adducts with topoisomerase II and DNA, ultimately causing double-strand breaks (28). Consequently, the genomic integrity of hematopoietic stem cells (HSCs) is markedly compromised, forcing the cells to arrest at the G₂/M phase and triggering widespread apoptosis (29) (Fig. 3).

In vitro assays indicate a >50% reduction in colony-forming units (CFU-GM/BFU-E) following metabolite exposure. Clinical data mirror this suppression, with exposed workers exhibiting reductions in leukocytes (18%), platelets (22%) and hemoglobin (15%) relative to controls (30). Aplastic anemia remains a critical complication, characterized histologically by hypocellular marrow and adipocyte replacement (31,32). Epidemiologically, exposure $>50 \text{ mg/m}^3$ associates with a 6–8-fold increased incidence of aplastic anemia (33,34). Furthermore, benzene is a confirmed leukemogen. IARC data associate benzene with a 3- to 5-fold elevated risk of AML, mediated via chromosomal aneuploidy (such as -5, -7), oncogene activation (*c-Myc*) and tumor suppressor inactivation (*p53*) (35,36).

Respiratory system inflammation and fibrosis. Benzene vapor acts as a potent respiratory irritant and pro-inflammatory agent (37). Acute high-level exposure ($>1,000 \text{ mg/m}^3$) triggers chemical bronchitis and pneumonitis, characterized by mucosal edema, goblet cell hyperplasia and airway obstruction (38,39). In severe acute poisoning, pulmonary edema occurs in ~15% of cases, with CT imaging revealing diffuse ground-glass opacities indicative of alveolar-capillary barrier disruption and a cytokine storm (TNF- α , IL-6) (40,41). Conversely, chronic low-dose exposure ($<50 \text{ mg/m}^3$) is implicated in chronic obstructive pulmonary pathologies (42). Workers in coating industries show a 28% prevalence of chronic bronchitis vs. 11% in controls (43). Spirometry indicates obstructive deficits, with reductions of 8–12% in vital capacity, forced vital capacity and forced expiratory volume in 1 sec (44). Long-term inhalation models in rats (50 mg/m^3)




Figure 1. PRISMA flow diagram detailing the literature search and study selection process. The flow diagram illustrates the systematic approach used to identify, screen, and select studies for this review. A total of 1,850 records were initially identified from databases. After removing 650 duplicate records, 1,200 records underwent title and abstract screening. A total of 800 records were excluded at this stage, leaving 400 reports sought for retrieval and full-text eligibility assessment. Among these, 100 reports were excluded due to irrelevant outcomes, and 52 were excluded for being in a non-English language. Ultimately, 248 eligible studies were included in the final review.

demonstrate alveolar septal thickening and collagen deposition, suggesting that chronic benzene-induced oxidative stress may drive pulmonary fibrotic remodeling and impair gas exchange (45,46).

Dermal barrier dysfunction and sensitization. Cutaneous toxicity arises from the solvent properties and sensitizing potential of benzene (47). As a lipophilic solvent, benzene extracts epidermal lipids (ceramides, fatty acids), disrupting

the stratum corneum barrier and increasing transepidermal water loss (48,49). This manifests clinically as xerosis, scaling and reduced resistance to pathogens. Additionally, benzene metabolites (such as hydroquinone) act as haptens, triggering allergic contact dermatitis (50). Symptoms range from erythema to vesiculation, with chronic exposure leading to lichenification (51). In rubber manufacturing cohorts, 42% of exposed workers exhibited dermatoses, with 15% suffering from recurrent allergic dermatitis (52). Pigmentary disorders,




Figure 2. Metabolic activation pathways of benzene and molecular mechanisms of hematopoietic toxicity. Benzene inhaled into the body is primarily metabolized in the liver by CYP2E1 into benzene oxide, which is further converted into phenolic intermediates, including phenol, catechol, and HQ. Alternatively, benzene oxide can be detoxified by glutathione S-transferase M1 to form SPMA and excreted in urine. The phenolic metabolites are transported via the systemic circulation to the bone marrow, where MPO catalyzes the oxidation of HQ into the markedly reactive ultimate toxicant, 1,4-BQ. Within HSCs, 1,4-BQ induces severe toxicity through multiple mechanisms: generating ROS that cause oxidative stress, forming covalent DNA adducts, and inhibiting topoisomerase II. These molecular events collectively lead to DNA double-strand breaks, ultimately triggering cellular apoptosis or driving leukemic transformation, such as AML. SPMA, S-phenylmercapturic acid; CYP2E1, cytochrome P450 2E1; MPO, myeloperoxidase; HQ, hydroquinone; ROS, reactive oxygen species; 1,4-BQ, 1,4-benzoquinone; HSCs, hematopoietic stem cells; AML, acute myeloid leukemia.




Figure 3. Metabolic bioactivation of benzene and the molecular mechanisms of hematopoietic toxicity. Hepatic metabolism: Inhaled benzene is primarily metabolized in the liver by CYP2E1 into reactive phenolic intermediates, including phenol and hydroquinone. Bone marrow damage: These metabolites are transported via the systemic circulation to the bone marrow microenvironment, where they induce severe oxidative stress, characterized by the accumulation of ROS and the rapid depletion of the antioxidant glutathione. Cellular damage in HSCs: Within HSCs, the synergistic effect of ROS and reactive intermediates leads to the inhibition of topoisomerase II and the formation of covalent DNA adducts. These molecular insults culminate in DSBs, forcing the HSCs into cell cycle arrest at the G₂/M phase and ultimately triggering apoptosis. CYP2E1, cytochrome P450 2E1; ROS, reactive oxygen species; HSCs, hematopoietic stem cells; DSBs, DNA double-strand breaks.

including hyperpigmentation or vitiligo-like leukoderma, affect ~8% of long-term workers, likely due to melanocyte

toxicity (53). Compromised skin integrity further predisposes workers to secondary bacterial infections (54).

Reproductive and developmental toxicity. Benzene acts as a reproductive toxicant and endocrine disruptor (55). In males, it crosses the blood-testis barrier, inducing oxidative stress in germ cells. Murine models show arrested spermatogenesis and apoptosis of spermatogonia (56). Clinically, exposed workers exhibit markedly reduced sperm concentration (35 vs. 60x10⁶/ml), decreased motility (Grade A+B reduced by ~25%) and elevated morphological abnormalities (18%) (57,58). Mechanistically, this is associated with increased sperm DNA fragmentation index driven by reactive oxygen species (59). In females, benzene disrupts the hypothalamic-pituitary-ovarian axis, causing menstrual dysfunction (oligomenorrhea) in 38% of exposed workers—a rate 2.3 times that of controls (60,61). Furthermore, benzene is teratogenic; it crosses the placental barrier, interfering with fetal organogenesis (62). Pregnancies in exposed workers are associated with a 60% increased risk of spontaneous abortion, a 15% preterm birth rate and a 3.2% incidence of congenital malformations (such as neural tube defects), highlighting its marked developmental toxicity (63).

Multi-organ carcinogenicity. Beyond leukemia, benzene (IARC Group 1 carcinogen) is associated with solid tumors (64,65). Cohort studies indicate a 2.1-fold increased risk of non-Hodgkin lymphoma and a 1.8-fold increase in multiple myeloma (66). Evidence also links exposure to lung and gastric cancers; for instance, coking plant workers exhibit a lung cancer mortality rate of 35 per 100,000 person-years (relative risk=2.7) (67,68). The carcinogenic mechanism is multifactorial, involving genotoxicity (DNA adduct formation), inhibition of DNA repair enzymes (such as XRCC1) and epigenetic dysregulation (69,70). Benzene simultaneously activates survival signaling (PI3K/Akt) and suppresses apoptosis (Bax downregulation), facilitating the clonal expansion of initiated cells (71). Long-term surveillance confirms a notably elevated all-cancer mortality rate in exposed populations (180 vs. 110 per 100,000 person-years) (72).

Immunotoxicity and immune surveillance suppression. Benzene is a potent immunotoxicant, compromising both innate and adaptive immunity (73). Inhalation studies demonstrate thymic atrophy and splenic T-cell depletion (30–40% reduction) (74). Human data reveal a global immunosuppressive profile: 15–20% lymphopenia, inverted CD4⁺/CD8⁺ ratios and hypogammaglobulinemia (IgG, IgA reduced by 10–15%) (75). Functionally, this manifests as increased susceptibility to infection. In influenza challenge models, benzene-exposed mice exhibited 45% mortality compared with 12% in controls (76). At the cellular level, oxidative stress impairs lymphocyte proliferation and cytokine production (IL-2, IFN- γ), thereby weakening immune surveillance against pathogens and neoplastic cells (77).

Cardiovascular impairment. Emerging evidence implicates benzene in cardiovascular pathology (78). Exposed workers show a higher prevalence of hypertension [28%; odds ratio (OR)=1.6] and coronary heart disease (1.5-fold increase) (79). Pathophysiologically, benzene promotes endothelial dysfunction by reducing nitric oxide availability and upregulating endothelin-1 (80,81). Furthermore, it disrupts lipid metabolism,

elevating total cholesterol (+20%) and triglycerides (+30%) while lowering high-density lipoprotein cholesterol, thus accelerating atherogenesis. Autonomic dysfunction is also observed: 32% of workers exhibit abnormal heart rate variability and sinus turbulence, indicating arrhythmogenic potential (82,83). Electrocardiogram abnormalities, such as ST-T changes, occur in ~18% of cases (84).

Ocular surface toxicity. Benzene vapor is an ocular irritant affecting the conjunctiva and cornea (85). Acute exposure (>500 mg/m³) causes immediate lacrimation and conjunctival hyperemia (86). Chronic low-level exposure induces ocular surface disease, including keratoconjunctivitis sicca (dry eye) (87). Diagnostic metrics reveal reduced Schirmer scores (tear secretion -30%) and shortened tear film break-up time (<10 sec) (88). In catastrophic leakage events (>2,000 mg/m³), chemical burns can cause corneal epithelial necrosis and permanent opacity, necessitating keratoplasty for visual rehabilitation (89).

Summary. As summarized comprehensively in Table I, the multi-systemic effects of benzene are characterized not only by severe hematological suppression but also by significant quantitative declines in nerve conduction, respiratory function and immune surveillance, underscoring the necessity for whole-body risk assessment.

3. Biomarkers of benzene

As detailed, benzene exerts profound multi-organ toxicity, affecting the nervous, cardiovascular and reproductive systems. However, it must be noted that the current landscape of validated benzene biomarkers notably skews toward hematotoxicity and genotoxicity (90). Specific effect biomarkers designed to reflect early benzene-induced neurotoxicity or cardiovascular dysfunction are currently lacking or remain strictly in the exploratory experimental phase (91). Therefore, the biomarkers discussed in the following sections primarily represent internal dose monitoring and hematopoietic/genomic impairments, highlighting a gap that future non-hematopoietic biomarker research must address (92). As summarized in Fig. 4, the landscape of benzene biomonitoring can be systematically categorized into exposure, effect and susceptibility biomarkers.

Exposure biomarkers. Exposure biomarkers reflect the internal dose of benzene absorbed by the human body (90). They mainly include the parent compound and its metabolites, which can be measured in biological samples such as blood, urine and exhaled air (89). These indicators provide objective and direct evidence for assessing exposure levels in both occupational and environmental contexts (93).

Benzene in blood. The concentration of benzene in blood is a direct marker of recent exposure (94). After inhalation or dermal absorption, a portion of benzene rapidly enters systemic circulation before being redistributed to tissues and organs (95). Due to its short half-life in blood (~4 h), blood benzene measurement is particularly suitable for evaluating acute exposure scenarios, such as accidental leakage events (96). For instance, blood benzene testing can be rapidly

Table I. Summary of benzene-induced multisystem toxicity: Clinical manifestations, mechanisms and key epidemiological findings.

Target system	Clinical manifestations	Key pathological mechanisms	Quantitative observations (from occupational cohorts)	(Refs.)
Hematopoietic	Leukopenia, thrombocytopenia, aplastic anemia, AML	Oxidative stress, DNA double-strand breaks, cell cycle arrest (G ₂ /M phase), stem cell apoptosis	Leukocytes ↓18%; Platelets ↓22%; AML risk elevated 3-5 fold	(24-36)
Nervous	Neurasthenia, cognitive decline, peripheral neuropathy	Neurotransmitter disruption (dopamine/serotonin), demyelination, hippocampal damage	Bilateral coordination ↓20%; Nerve conduction velocity ↓ 3-5 m/sec	(13-23)
Respiratory	Cough, dyspnea, pulmonary fibrosis, chronic bronchitis	Alveolar epithelial injury, cytokine storm (TNF- α , IL-6), collagen deposition	Chronic bronchitis prevalence: 28% (vs. 11% control); FEV ₁ ↓8-12%	(37-46)
Reproductive (Male)	Oligospermia, asthenospermia, teratospermia	Oxidative stress in germ cells, DNA fragmentation, apoptosis of spermatogonia	Sperm concentration: 35x10 ⁶ /ml (vs. 60x10 ⁶ /ml control); Abnormal morphology: 18%	(55-59)
Reproductive (Female)	Menstrual disorders, spontaneous abortion, fetal defects	Endocrine disruption (HPO axis), placental barrier crossing, interference with organogenesis	Menstrual abnormalities: 38%; Miscarriage risk ↑ 60%; Preterm birth rate: 15%	(60-63)
Immune	Increased susceptibility to infection, lymphopenia	Thymic atrophy, suppression of T-cell proliferation, cytokine dysregulation (IL-2, IFN- γ)	Lymphocytes ↓15-20%; CD4 ⁺ /CD8 ⁺ ratio inversion; IgG/IgA ↓10-15%	(73-77)
Cardiovascular	Hypertension, arrhythmias, atherosclerosis	Endothelial dysfunction (NO↓, ET-1↑), lipid metabolism disorder, autonomic dysregulation	Hypertension prevalence: 28%; HRV abnormalities: 32%; ST-T changes: ~18%	(78-84)
Dermal/ocular	Dermatitis, xerosis, conjunctivitis, corneal injury	Lipid extraction (stratum corneum disruption), sensitization (hapten formation)	Skin disorder incidence: 42%; Tear secretion ↓30%; BUT <10 sec	(47-54,85-89)

AML, acute myeloid leukemia; FEV₁, forced expiratory volume in 1 sec; HPO, hypothalamic-pituitary-ovarian; NO, nitric oxide; ET-1, endothelin-1; HRV, heart rate variability; BUT, break-up time.

applied to rescue personnel or nearby residents exposed to high concentrations over a short period (97).

The primary analytical method is gas chromatography (GC) (98). Blood samples are pretreated (for example by solid-phase extraction or headspace sampling), then introduced into the chromatograph, where benzene is separated and quantified using detectors such as flame ionization detection or mass spectrometry (MS) (99). However, a critical limitation lies in the strict timing of sample collection; blood must be obtained within a narrow time window (ideally within 24 h post-exposure), as concentrations markedly decline due to metabolism and excretion (100). Delayed sampling may thus underestimate true exposure levels (101).

Benzene in exhaled air. Exhaled air analysis offers a non-invasive approach to monitoring benzene exposure and is associated with blood concentrations (102). Since a fraction of absorbed benzene is excreted via respiration at a relatively stable rate, this biomarker is well-suited for real-time exposure assessment in occupational settings (103). For example, exhaled air collection during paint-spraying operations allows immediate estimation of exposure levels during work shifts (104).

The commonly used detection technique is solid-phase microextraction coupled with GC-MS (105). Here, benzene is adsorbed onto a solid-phase microextraction fiber, desorbed into the chromatograph, and identified by MS (106). This approach provides high sensitivity, operational simplicity and




Figure 4. Landscape of traditional and emerging biomarkers for benzene exposure and toxicity. A comprehensive classification of benzene biomarkers categorized into exposure, effect and susceptibility markers. Exposure biomarkers reflect the internal dose, encompassing unmetabolized benzene and tracing the paradigm shift from traditional urinary metabolites (phenol, hydroquinone) typically used for high-concentration scenarios, to specific/emerging metabolites such as tt-MA and SPMA. Notably, SPMA is recommended for biological monitoring of low-dose exposure due to its superior specificity. Effect biomarkers capture early biological damage, predominantly featuring hematological indices (reduced white blood cell and platelet counts) and structural molecular alterations indicative of genotoxicity (chromosomal aberrations, micronuclei, and adduct formation). Susceptibility biomarkers, primarily representing genetic polymorphisms, act as modulators that influence the individual vulnerability and the mechanistic link between benzene exposure and subsequent toxicological effects. Tt-MA, trans, trans-muconic acid; SPMA, S-phenylmercapturic acid; WBC, white blood cell; SCE, sister chromatid exchange.

notably, the advantage of being repeatable and non-invasive, making it suitable for large-scale workplace screening (107).

Nevertheless, exhaled benzene concentrations are easily influenced by respiratory parameters (such as breathing rate and depth) and ambient environmental contamination (108). Thus, standardized sampling protocols and strict quality control are essential to ensure reliability (109).

Phenol in urine. Phenol is one of the principal urinary metabolites of benzene and has long been used as a biomarker for occupational exposure (110). After benzene is metabolized by the hepatic cytochrome P450 enzyme system, phenol is produced and subsequently conjugated with sulfuric acid or glucuronic acid (111). A total of ~30% of benzene is excreted as conjugated phenol, whereas free phenol accounts for only ~5% (112). Urinary phenol levels generally associate with the extent of benzene exposure and typically normalize within 24-48 h after exposure cessation (113).

Detection methods include the aminopyrine colorimetric method and GC (114). The aminopyrine method relies on a color reaction between phenolic compounds and specific reagents, whereas GC provides higher sensitivity (down to

0.01 mg/l) and reproducibility (115). For example, a study on paint-stripping workers demonstrated a notable dose-response relationship, where workplace benzene concentrations ranging from 0.6 to 65.9 mg/m³ corresponded with urinary phenol levels of 4.3-52.8 mg/l (116).

However, urinary phenol has limitations. Baseline levels in the general population range from 0.15-0.25 mg/l (and can be higher in smokers), which reduces specificity for low-level exposures (117). Moreover, notable inter-individual variability exists—phenol excretion under similar exposure conditions may differ by as much as 12-fold, partly due to differences in liver function and the influence of medications (such as phenobarbital), which alter cytochrome P450 activity (118). Therefore, urinary phenol is more reliable for monitoring high-concentration exposure, whereas its sensitivity for low-level exposure remains inadequate (119).

Hydroquinone in urine. Hydroquinone is a more specific urinary metabolite of benzene compared with phenol and provides enhanced accuracy for exposure assessment (120). Following benzene oxidation to benzene oxide, further metabolism yields hydroquinone, which is excreted in urine (121). Quantification is typically performed using high-performance

liquid chromatography (HPLC) with ultraviolet detection after appropriate sample pretreatment (122).

Epidemiological investigations show that urinary hydroquinone levels exhibit a notable dose-response relationship with benzene exposure concentration (123). Compared with phenol, hydroquinone is less affected by confounding factors and therefore more reliable in detecting low-concentration exposures (124). Nonetheless, hydroquinone measurement is not completely specific, as certain dietary components or medications may also elevate urinary hydroquinone, necessitating combined measurement with phenol or other metabolites to improve diagnostic accuracy (125).

Catechol in urine. Catechol is a minor urinary metabolite of benzene and may serve as a supplementary biomarker of exposure (126). Its metabolic pathway is similar to that of hydroquinone, both being products of benzene oxidative metabolism (127). Although catechol is less commonly employed than phenol and hydroquinone in routine biomonitoring, several studies suggest that combined analysis of catechol with other metabolites can provide a more comprehensive picture of benzene biotransformation and exposure burden (128-131). Detection is typically performed using HPLC (129). However, its relatively low urinary concentration and susceptibility to various endogenous and exogenous interferences limit its specificity and sensitivity (130). At present, catechol is primarily used as an auxiliary indicator within a biomarker panel rather than as a standalone marker of benzene exposure (131).

tt-MA in urine. tt-MA is a benzene metabolite generated via the epoxidation pathway, with a half-life of ~16 h (132). This relatively long persistence makes tt-MA suitable for detecting low-dose or subacute benzene exposure (133). Benzene oxide, an intermediate metabolite, is further metabolized into muconic acid, among which tt-MA is the predominant isomer (134).

Detection methods such as GC-MS and HPLC-MS/MS enable accurate qualitative and quantitative analysis of tt-MA in urine (135). Epidemiological studies have demonstrated that urinary tt-MA levels are positively associated with both the concentration and duration of occupational benzene exposure (135,136). Furthermore, tt-MA decreases relatively slowly after cessation of exposure, thus serving as a retrospective indicator of recent exposure (137). Accordingly, tt-MA is widely recognized as a valuable biomarker for monitoring low-level occupational benzene exposure and plays an notable role in environmental health risk assessment (138).

SPMA in urine. SPMA is produced via the conjugation of benzene oxide with glutathione under the catalysis of glutathione S-transferases (GSTs), followed by subsequent metabolic reactions leading to urinary excretion (139). SPMA is considered a markedly specific and sensitive biomarker of benzene exposure, even at low concentrations (140). Studies indicate that urinary SPMA levels notably increase in workers exposed to low ambient benzene levels, and these levels associate with biomarkers of oxidative stress, such as 8-hydroxy-2'-deoxyguanosine, suggesting potential genotoxic risk even at low-dose exposure (140,141).

Advanced analytical techniques such as HPLC-MS/MS allow sensitive detection of trace SPMA in urine with minimal

interference from other sources (142). Given its high specificity, SPMA is increasingly regarded as a robust biomarker for early biological monitoring of benzene exposure and has promising potential for occupational health surveillance and risk prevention (143). As comprehensively compared in Table II, while traditional metabolites such as phenol suffer from low specificity and high background interference, emerging biomarkers such as SPMA and tt-MA offer superior sensitivity for low-dose exposure assessments, underscoring the critical transition in modern biomonitoring strategies.

Effect biomarkers. Effect biomarkers reflect biological damage or functional alterations induced by benzene exposure (144). Since the hematopoietic system is the primary toxicological target of benzene, most effect biomarkers are associated with hematopoietic suppression and genotoxicity (145).

Peripheral white blood cell (WBC) count. A decrease in peripheral WBC count, particularly neutropenia, is a common early hematological effect of benzene exposure (146). Benzene and its metabolites impair the proliferation and differentiation of hematopoietic stem and progenitor cells, resulting in reduced leukocyte production (147). Occupational studies have shown that chronic low-level benzene exposure leads to a gradual decline in WBC count, which positively associates with exposure intensity and duration (148,149). For instance, health examinations in benzene-exposed shoe factory workers revealed notably lower WBC counts and neutrophil proportions compared with reference values, indicating compromised immune function and increased susceptibility to infection (149).

Although WBC monitoring is useful for early detection of hematotoxicity, it lacks specificity since infections, medications and other conditions can also reduce leukocyte levels (150). Thus, WBC count should be interpreted in conjunction with other biomarkers (151).

Platelet count. Thrombocytopenia is another hematological effect of benzene exposure, reflecting bone marrow suppression of megakaryocyte development and platelet production, as well as enhanced platelet destruction (152). Clinically, benzene-related thrombocytopenia often manifests as coagulation dysfunction, including epistaxis, gingival bleeding and cutaneous ecchymoses (153). Platelet reduction is dose-dependent, with more pronounced decreases in populations exposed to higher benzene concentrations (154). Given its simplicity and clinical availability, platelet count is a valuable indicator of benzene-induced hematotoxicity, although differential diagnoses such as autoimmune diseases or hypersplenism must be excluded (155).

Red blood cell count and hemoglobin. Chronic benzene exposure may result in anemia, characterized by reduced red blood cell count or hemoglobin concentration (156). Mechanistically, benzene inhibits hematopoietic stem cell activity and disrupts key enzymes involved in erythropoiesis (157). Additionally, oxidative stress induced by benzene metabolites can damage erythrocyte membranes and shorten red cell lifespan. Clinically, patients with chronic benzene poisoning often present with pallor, fatigue and dizziness, alongside hematological findings of anemia (158). Routine monitoring of red blood cell indices in exposed populations is useful for early detection of hematopoietic impairment,

Table II. Comparative evaluation of traditional and emerging biomarkers for benzene exposure assessment.

Biomarker category	Specific biomarker	Matrix	Metabolic pathway	Half-life	Sensitivity (low-dose)	Specificity	Key limitations	(Refs.)
Parent compound	Benzene	Blood	Unmetabolized	~4 h	High	High	Invasive; rapid decline requires immediate sampling (<24 h).	(96)
	Benzene	Breath	Excretion via lungs	Minutes	High	High	Highly variable; influenced by breathing rate and background air.	(102,103)
Traditional metabolites	Phenol	Urine	CYP2E1 oxidation	24-48 h	Low	Low	High background in general population; lacks correlation at <10 ppm exposure.	(113)
	Hydroquinone	Urine	CYP2E1 oxidation	24-48 h	Moderate	Low	Influenced by dietary intake and medications; not specific to benzene.	(123,124)
Specific metabolites	<i>trans, trans</i> -muconic acid	Urine	Ring opening	~16 h	High	Moderate	False positives due to dietary sorbic acid (preservative); influenced by smoking.	(132)
	S-phenylmercapturic acid	Urine	GSH conjugation (GSH S-transferases)	12-48 h	Very high	High	Requires sensitive detection (LC-) MS/MS); considered the gold standard for low-level exposure.	(139,140)
Macromolecular adducts	Albumin/Hemoglobin Adducts	Blood	Covalent binding	Weeks to Months	High	High	Reflects cumulative exposure; technically demanding; primarily for research.	(181)

CYP2E1, cytochrome P450 2E1; PPM, parts per million; GSG, glutathione; LC-MS/MS, liquid chromatography tandem mass spectrometry.

although the multifactorial etiology of anemia necessitates comprehensive evaluation (159).

Chromosome aberrations in bone marrow cells. Benzene metabolites are genotoxic and can induce structural

chromosome aberrations such as breaks, translocations and deletions (160). Cytogenetic analysis of bone marrow cells, often via chromosome banding, enables visualization of these aberrations and quantification of their frequency (161).

Occupational studies consistently report elevated rates of chromosomal abnormalities in benzene-exposed populations, with a dose-response relationship observed (162-164). Since chromosomal aberrations are generally irreversible, they may predispose to genetic instability and tumorigenesis (163). Despite its diagnostic value, chromosomal aberration testing requires specialized expertise and high-quality samples, limiting its application in large-scale screening (164).

Sister chromatid exchange (SCE). SCE serves as a marker of DNA damage and repair activity (165). Under normal conditions, SCE frequency is low, but exposure to mutagens such as benzene markedly increases its occurrence (166). SCE analysis involves BrdU incorporation into cultured lymphocytes, followed by differential staining and microscopic evaluation (167). Numerous studies show markedly higher SCE frequencies in benzene-exposed workers compared with unexposed controls, associating with both exposure level and duration (168,169). Although SCE is sensitive to DNA damage, it lacks specificity since other environmental and pathological factors can also elevate SCE frequency; thus, it should be interpreted alongside other genotoxicity indicators (169).

Micronuclei. Micronuclei are extranuclear chromatin bodies formed during mitosis when chromosome fragments or whole chromosomes fail to be incorporated into daughter nuclei (170). Elevated micronucleus frequency in peripheral lymphocytes or bone marrow cells indicates chromosomal damage and is widely used as a biomarker of genotoxicity (171). Detection methods include conventional Giemsa staining and flow cytometry, both of which facilitate quantification of micronucleated cells (172). Multiple studies have documented notably higher micronucleus rates in benzene-exposed populations, with a positive dose-response relationship (173,174). Micronucleus assays are simple and suitable for large-scale biomonitoring, although their low specificity necessitates complementary testing (174).

DNA adducts. DNA adducts are covalent complexes formed between reactive benzene metabolites (such as benzoquinone) and DNA, directly reflecting molecular damage (175). Adduct formation interferes with DNA replication and transcription, thereby increasing mutagenic and carcinogenic risk (176). Detection methods include ELISA, which utilizes specific antibodies for semiquantitative analysis, and HPLC-MS/MS, which provides precise structural and quantitative information (177). In benzene-exposed populations, multiple types of DNA adducts have been identified, with levels linked to exposure intensity (178). DNA adduct analysis is therefore crucial for elucidating benzene genotoxic mechanisms and evaluating long-term health risks, and it remains a research focus in toxicogenomics (179).

Hemoglobin adducts. Hemoglobin adducts are stable complexes formed between benzene metabolites and hemoglobin residues (180). Given the long half-life of hemoglobin, these adducts provide an integrated measure of cumulative benzene exposure over weeks to months (181). MS-based techniques enable their detection and quantification (182). Occupational studies, such as those involving long-term gasoline station attendants, have reported elevated hemoglobin adduct levels, associating with exposure duration and intensity (183). This biomarker offers unique advantages in

tracing chronic low-level exposure, although specialized instrumentation and further research on dose-response relationships are required to strengthen its utility in health risk assessment (184).

Susceptibility biomarkers. Susceptibility biomarkers reflect inter-individual genetic variations that influence vulnerability to benzene toxicity (185). They are mainly associated with polymorphisms in genes encoding metabolic enzymes and DNA repair proteins (186). Such biomarkers can help identify high-risk populations and support the development of personalized protection strategies in occupational and environmental settings (187).

Cytochrome P450 enzyme system (CYP). The CYP plays a central role in benzene metabolism, with *CYP2E1* being the most critical enzyme (188). The *CYP2E1* gene exhibits polymorphisms such as the *5B* mutation, which alters enzyme activity and affects benzene metabolic rates (189). Individuals carrying the *CYP2E15B* variant tend to show enhanced enzymatic activity, leading to accelerated formation of toxic metabolites and increased susceptibility to benzene-induced hematotoxicity (190). Occupational studies have demonstrated that workers with the *CYP2E15B* allele exhibit elevated levels of benzene metabolites in blood, higher chromosomal aberration frequencies, and increased micronucleus formation in bone marrow cells compared with wild-type carriers under equivalent exposure levels (191). Genotyping of *CYP2E1* polymorphisms can be performed using polymerase chain reaction-restriction fragment length polymorphism, enabling identification of at-risk individuals for targeted preventive interventions (192).

Beyond *CYP2E1*, *CYP1A1* and *CYP1B1* also contribute to benzene metabolism. Polymorphic variants such as *CYP1A12A* and *2B* enhance benzene bioactivation (193). For instance, carriers of *CYP1A12A* have been shown to display notably higher urinary hydroquinone-to-phenol ratios, suggesting more efficient conversion to toxic intermediates (194). A 2023 cohort study of 523 benzene-exposed workers in southern China revealed that individuals harboring both *CYP2E15B* and *CYP1A12A* mutations had a 2.3-fold higher frequency of micronucleated blood cells compared with wild-type individuals (95% CI: 1.8-2.9), particularly at exposure levels >10 mg/m³ (195). These findings highlight the importance of polygenic interactions in determining susceptibility to benzene toxicity (196). Furthermore, marked ethnicity disparities exist in the distribution of *CYP2E1* polymorphisms. For example, the frequency of the vulnerable *CYP2E1*5B* variant is notably higher in East Asian populations (20-30%) compared with Caucasian populations (2-5%) (189).

GST. The GST family mediates detoxification of benzene metabolites (197). Among them, the null genotypes of *GSTM1* and *GSTT1* are the most studied (198-200). *GSTM1* catalyzes conjugation of glutathione with reactive metabolites such as benzoquinone; individuals with the *GSTM1* null genotype lack enzymatic activity and have impaired detoxification capacity (201,202). A meta-analysis of 12 case-control studies (1,892 cases and 3,247 controls) reported that *GSTM1* deletion increased the risk of benzene-induced leukemia by 1.62-fold (OR=1.62, 95% CI: 1.35-1.94) (203,204).

Table III. Genetic polymorphisms in metabolic and DNA repair enzymes associated with susceptibility to benzene toxicity.

Gene category	Gene symbol	Function	Key polymorphism	Functional consequence	Associated risk (odds ratio/findings)	(Refs.)
Bioactivation (Phase I)	<i>CYP2E1</i>	Oxidative metabolism	<i>CYP2E1*5B</i>	Increased enzyme activity (rapid metabolizer)	Elevated micronucleus frequency and chromosomal aberrations.	(188-191)
	<i>CYP1A1</i>	Oxidative metabolism	<i>CYP1A1*2A</i>	Enhanced bioactivation	Higher urinary hydroquinone/phenol ratio.	(192-194)
Detoxification (Phase II)	<i>GSTM1</i>	GSH conjugation	Null genotype (Deletion)	Loss of function (impaired detoxification)	1.62-fold increased leukemia risk; 18.7% higher SPMA levels.	(201-204)
	<i>GSTT1</i>	GSH conjugation	Null genotype (Deletion)	Loss of function	Combined <i>GSTM1/GSTT1</i> null: 2.17-fold increased leukemia risk.	(197-205)
	<i>NQO1</i>	Quinone reduction	<i>NQO1*2</i> (C609T)	Null activity	2.03-fold increased leukemia risk; 37.2% increase in DNA adducts.	(206-208)
DNA repair	<i>XRCC1</i>	BER (base excision)	Arg399Gln	Reduced repair capacity	1.45-fold risk of hematotoxicity; increased micronuclei.	(211-213)
	<i>XPB</i> (<i>ERCC2</i>)	NER (nucleotide excision)	Lys751Gln	Reduced helicase activity	Notable association with chromosomal aberrations.	(214-216)
	<i>p53</i>	Cell cycle control	Arg72Pro	Altered apoptosis	23.6% reduction in apoptotic clearance of damaged cells.	(217- 220)

BER, base excision repair; NER, nucleotide excision repair; GSH, glutathione; CYP2E1, cytochrome P450 2E1; CYP1A1, cytochrome P450 family 1 subfamily a member 1; NQO1, NAD(P)H quinone oxidoreductase 1; GSTM1, glutathione S-transferase Mu 1; GSTT1, glutathione S-transferase theta 1; XRCC1, X-ray repair cross-complementing protein 1.

The combined effect of GSTT1 and GSTM1 double deletions further elevated risk to 2.17-fold (OR=2.17, 95% CI: 1.76-2.67) (205).

Quinone Reductase 1 (*NQO1*). *NQO1* catalyzes the detoxification of benzoquinone by reducing it to hydroquinone (206). The *NQO12* (C609T) polymorphism abolishes enzyme activity, and homozygous carriers accumulate 2.5-fold higher benzoquinone levels compared with wild-type individuals (207). A prospective cohort study (5-year follow-up, n=836) demonstrated that workers with the *NQO12/2* genotype had markedly elevated DNA adduct levels (+37.2%) and a higher incidence of leukemia (hazard ratio=2.03, 95% CI: 1.12-3.68) (208). The combined presence of *NQO12* and *GSTM1* deletion further increased the risk of DNA damage by 3.1-fold, indicating that multi-gene testing may improve accuracy in identifying susceptible populations (209). Similar to other metabolic enzymes, the prevalence of the *NQO1*2* variant exhibits notable ethnicity variation, with the mutant allele frequency reaching 30-40% in Asian cohorts compared with ~15% in Caucasian cohorts (208).

***XRCC1* gene.** The *XRCC1* gene encodes a DNA repair protein involved in single-strand break repair (210). Its Arg399Gln polymorphism (rs25487) reduces repair efficiency (211). Carriers of the Gln allele have been reported

to exhibit a 29.4% higher micronucleus frequency following benzene exposure compared with Arg homozygotes (212). A 2021 meta-analysis of six studies confirmed that *XRCC1* Arg399Gln is associated with an elevated risk of benzene-induced hematotoxicity (OR=1.45, 95% CI: 1.18-1.78), particularly in populations with cumulative benzene exposure >100 mg/year/m³ (213).

***XPB* (*ERCC2*) gene.** *XPB* encodes a helicase essential for nucleotide excision repair (214). The Lys751Gln polymorphism (rs13181) reduces enzymatic activity, leading to compromised DNA repair capacity. Benzene-exposed individuals carrying the Gln allele show markedly higher chromosomal aberration rates, with a positive association to exposure levels (215). A study of 112 patients with benzene-induced leukemia found a notably higher prevalence of the Gln/Gln genotype (38.4%) compared with healthy controls (21.5%), suggesting that *XPB* Lys751Gln is a potential risk marker for benzene-related leukemia (216).

***ATM* and *p53* genes.** The *ATM* gene plays a crucial role in DNA double-strand break repair (217). Its rs189037 polymorphism has been linked to increased chromosomal instability in benzene-exposed populations (218). Similarly, the codon 72 polymorphism (Arg72Pro) of the *p53* gene affects cell cycle regulation (219). In benzene-exposed individuals carrying the




Figure 5. Genetic susceptibility network and multi-gene interactions in benzene-induced toxicity. The individual vulnerability to benzene toxicity is co-amplified by genetic polymorphisms across three critical metabolic and repair pathways: (1) Enhanced bioactivation: Polymorphisms in cytochrome P450 enzymes (CYP2E1*5B, CYP1A1*2A) increase enzymatic activity, accelerating the hepatic formation of reactive metabolites and significantly increasing micronuclei frequencies in blood cells. (2) Impaired detoxification: Null genotypes in glutathione S-transferases (*GSTM1*, *GSTT1*) and polymorphisms in quinone reductase 1 (*NQO1**2) compromise the clearance of toxic intermediates, with combined *GSTM1*/*GSTT1* deletions synergistically elevating the risk of benzene-related leukemia by 2.17-fold. (3) Compromised DNA repair: Variants in DNA repair and cell cycle control genes (*XRCC1* Arg399Gln, *XPD* Lys751Gln, *ATM* rs189037 and *p53* Arg72Pro) impair single/double-strand break repair and disrupt the apoptosis of damaged cells. Together, these genetic variations drive cumulative DNA damage, genomic instability, and chromosomal aberrations, emphasizing the necessity of integrating multi-gene profiling into comprehensive risk assessments. GSTs, glutathione S-transferases; CYP2E1, cytochrome P450 2E1; CYP1A1, cytochrome P450 family 1 subfamily A member 1; NQO1, NAD(P)H quinone oxidoreductase 1; *GSTM1*, glutathione S-transferase mu 1; *GSTT1*, glutathione S-transferase theta 1; *XRCC1*, X-ray repair cross-complementing protein 1.

Pro allele, lymphocyte apoptosis rates are reduced by 23.6%, indicating impaired clearance of damaged cells (220).

Combinatorial assessment of these genetic polymorphisms allows the construction of susceptibility scoring models for benzene toxicity, offering a more comprehensive tool for individualized risk evaluation and occupational health management (221). To systematically illustrate this, Table III details the specific functional consequences and quantitative risks—such as elevated odds ratios for leukemia and hematotoxicity—associated with key polymorphisms across bioactivation, detoxification, and DNA repair pathways, which directly correspond to the integrated susceptibility network mapped in Fig. 5.

Ethnicity disparities and regulatory implications. As detailed in the preceding subsections, ethnic differences in gene frequency play a pivotal role in population-specific susceptibility, with Asian populations often exhibiting higher frequencies of vulnerable genotypes (*GSTM1* null, CYP2E1*5B and *NQO1**2) (201–203). These distinct genetic landscapes raise a critical regulatory question regarding Occupational Exposure Limits (OELs) (203). Currently, OELs vary markedly across regions, such as China's PC-TWA of 6 mg/m³ vs. the US ACGIH TLV of 0.5 ppm. Given these genetic disparities, relying on a universal or less stringent OEL may leave substantial proportions of the workforce inadequately protected (204). Consequently, future standard-setting bodies must factor in ethnic genetic susceptibility, potentially moving toward region-specific or genetically tailored occupational exposure thresholds (205).

Emerging and comprehensive biomarkers. With advances in analytical technologies, exhaled breath metabolomics and multi-biomarker integration strategies have emerged as novel approaches for benzene exposure assessment (222). These methods overcome the limitations of single biomarkers and improve both monitoring accuracy and early warning efficiency (223).

Exhaled breath metabolomics: A promising non-invasive tool. Exhaled breath metabolomics is a newly developed non-invasive technique characterized by convenient sample collection, real-time monitoring and suitability for longitudinal surveillance. It employs high-resolution analytical platforms—such as GC-MS, LC-MS and proton transfer reaction (PTR)-MS, to profile small-molecule metabolites (typically <1,000 Da) in exhaled air, and links them to physiological or pathological states (224).

Animal studies have identified two metabolite classes negatively associated with peripheral WBC decline: ω -carboxylic fatty acids (such as valeric acid- ω -carboxylic acid, C₅H₁₀O₃; hexanoic acid- ω -carboxylic acid, C₆H₁₂O₃) and glutamic acid. Elevated ω -carboxylic fatty acids, intermediates of β -oxidation, may indicate disrupted energy metabolism in the bone marrow hematopoietic microenvironment (225). Conversely, reduced glutamic acid levels may reflect impaired immune cell production or function, showing causal links with WBC reduction (226).

These findings suggest exhaled breath metabolites as promising non-invasive markers of hematopoietic impairment. Portable devices enable real-time, bedside analysis, making this approach particularly valuable for long-term surveillance of

exposed workers or patients undergoing chemotherapy (227). Preliminary cohort data from benzene-exposed workers show correlation coefficients ($r=-0.62$ to -0.71) between exhaled $C_5H_{10}O_3/C_6H_{12}O_3$ and WBC counts, consistent with animal results ($r=-0.58$ to -0.67), thereby confirming translational potential (228-230).

Multi-biomarker integration: Overcoming the limitations of single indicators. Single biomarkers often fail to capture low-dose pollutant exposure-effect relationships due to limited specificity, interference and narrow coverage (231). By contrast, the multi-marker integration strategy achieves a comprehensive evaluation of exposure intensity and accumulated damage by combining multiple biomarkers across temporal and mechanistic dimensions (230-232). This approach has been validated in low-dose exposure scenarios involving benzene, formaldehyde, and polycyclic aromatic hydrocarbons (PAHs) (231).

The strategy of 'interference correction + effect complementation' improves exposure assessment accuracy, therefore, improving low-dose exposure assessment (232). For instance, tt-MA, a specific benzene metabolite, can be confounded by smoking and dietary factors, as urinary tt-MA levels in smokers are ~4-fold higher than in non-smokers (233). A study on benzene-exposed workers proposed a composite detection protocol integrating tt-MA, PAH-DNA adducts (PLG) and peripheral blood micronucleus frequency: i) tt-MA, reflects short-term exposure (1-3 days); interference corrected via smoking questionnaires (234); ii) PLG, indicates medium-term cumulative exposure (half-life 1-3 months), unaffected by smoking (235); and iii) micronucleus frequency, reflects chromosomal damage, establishing a causal link between exposure and genotoxicity (236). This combined approach achieved 89% accuracy in identifying low-dose benzene exposure (8 h TWA <0.5 mg/m³), compared with 62% using tt-MA alone (237).

Multi-marker integration can be structured along exposure timelines, forming a chain of 'acute response-cumulative damage', therefore, allowing dynamic monitoring. Acute phase (hours to days): Short half-life metabolic biomarkers (such as tt-MA and SPMA) allow rapid detection (238). For example, in the 2024 styrene storage tank leakage incident, urinary SPMA screening within 6 h identified three overexposed workers, preventing acute poisoning (239). Cumulative phase (months to years): Long half-life biomarkers (hemoglobin adducts, DNA adducts) and epigenetic markers (*STAT3* methylation) are employed (240). Workers with >5 years of benzene exposure showed a *STAT3* methylation positivity rate of 68 vs. 21% in those exposed <1 year, with methylation levels negatively associated with WBC count (241).

Clinical applications are increasingly adopting a combined panel of acute, cumulative, and epigenetic biomarkers in annual occupational health surveillance. Tracking biomarker trajectories over 3 years enables prediction of hematopoietic impairment 1-2 years in advance, extending the early warning window beyond traditional hematological testing (242).

4. Integration of biomarkers into precision occupational health surveillance

Taken together, exhaled breath metabolomics and multi-biomarker integration strategies represent two

complementary directions at the frontier of benzene exposure monitoring (243). Exhaled breath metabolomics, with its advantages of non-invasiveness, convenience and real-time assessment, provides novel insights into dynamic changes in hematopoietic function and holds translational promise for large-scale occupational surveillance (244). Multi-marker integration, by combining exposure biomarkers, effect biomarkers and epigenetic signatures, overcomes the inherent limitations of single indicators and enables a more comprehensive evaluation of both short-term exposure and long-term cumulative effects (245).

To actualize this paradigm shift, AI and machine learning (ML) algorithms are increasingly being employed to decode complex multi-omics datasets. Advanced ML models, such as Random Forest and Support Vector Machines, excel at identifying non-linear patterns within high-dimensional metabolomic and genomic data (246). By feeding simultaneous variables-such as exhaled ω -carboxylic fatty acids, genetic polymorphisms (*GSTM1* null) and traditional metabolites (SPMA)-into these AI algorithms, researchers can construct robust predictive models (247). These AI-driven frameworks not only enhance the accuracy of detecting low-dose exposures but also automatically stratify workers into personalized risk tiers, alerting occupational physicians to sub-clinical hematotoxicity before irreversible bone marrow failure occurs (248).

Looking ahead, these approaches are expected to converge into integrated monitoring frameworks that leverage high-throughput omics platforms and AI-driven data analytics (246). Such frameworks may facilitate the construction of individualized biomarker panels that are predictive of early hematotoxicity and long-term carcinogenic risks (247). To operationalize the dynamic monitoring paradigm illustrated in Fig. 6, we propose a hierarchical strategy for integrated benzene health surveillance (Table IV). This approach stratifies occupational monitoring into four actionable clinical tiers, ranging from acute exposure screening (Tier 1) to lifetime susceptibility profiling (Tier 4). However, despite the promise of exhaled breath metabolomics (Tier 2) and epigenetic profiling (Tier 3), their routine implementation in large-scale occupational surveillance faces notable clinical and logistical hurdles (246,247). Cost-effectiveness remains a primary barrier, as high-resolution LC-MS/MS or epigenetic sequencing is substantially more expensive than traditional complete blood counts. Furthermore, deploying portable analytical devices, such as PTR-MS, in resource-limited factory settings presents standardization challenges. The stability of breath metabolites can be severely compromised by field conditions, including high ambient humidity and fluctuating factory temperatures. Therefore, optimizing sample collection protocols and developing robust point-of-care devices are prerequisite steps before these advanced tiers can be broadly integrated into occupational health guidelines (248).

5. Conclusion and future perspectives

Benzene remains a pervasive occupational hazard, inducing profound multi-systemic toxicity that extends far beyond classic hematopoiesis to encompass neurotoxic, cardiovascular and reproductive impairments. Despite decades of research,

Table IV. Proposed hierarchical strategy for integrated benzene health surveillance: From exposure to early effect.

Monitoring tier	Objective	Recommended biomarker panel	Time window	Clinical utility
Tier 1: Exposure screening	Rapid identification of recent exposure & ‘body burden’	Urinary SPMA + breath benzene	Hours to days (acute)	Gold standard for low-dose compliance; differentiates occupational vs. background exposure.
Tier 2: Early effect (sub-clinical)	Detect early biological perturbations before disease onset	Exhaled breath metabolomics (fatty acids) + micronuclei (CBMN)	Weeks to months	Non-invasive warning of hematopoietic microenvironment stress and genotoxicity.
Tier 3: Cumulative risk	Assess long-term damage and cancer risk	Hemoglobin/DNA adducts + epigenetic markers (<i>STAT3</i> methylation)	Months to years (chronic)	Reflects historical burden; predicts long-term hematological malignancy risk.
Tier 4: Susceptibility profiling	Identify high-risk individuals for personalized protection	Genotyping panel (<i>CYP2E1</i> , <i>GSTM1</i> , <i>NQO1</i> , <i>XRCC1</i>)	Lifetime (static)	Personalized risk stratification; guides job placement and protective equipment standards.

CYP2E1, cytochrome P450 2E1; CYP1A1, cytochrome P450 family 1 subfamily A member 1; NQO1, NAD(P)H quinone oxidoreductase 1; GSTM1, glutathione S-transferase Mu 1; GSTT1, glutathione S-transferase theta 1; XRCC1, x-ray repair cross-complementing protein 1.




Figure 6. Integrated and dynamic monitoring framework for precision occupational health in benzene exposure. The framework illustrates the paradigm shift from traditional reactive monitoring to proactive precision health. The system synthesizes multi-dimensional data across two temporal branches: Temporal Branch A focuses on acute phase screening (hours to days) using short half-life metabolites such as tt-MA and SPMA for real-time alerts; Temporal Branch B targets cumulative burden (months to years) utilizing long half-life markers such as DNA/hemoglobin adducts and epigenetic alterations (STAT3 methylation). Concurrently, exhaled breath metabolomics (ω -carboxylic fatty acids) provides an integrated, non-invasive surveillance tool directly associated with hematotoxicity. Through an AI-driven analytics funnel, these diverse multi-omics data (metabolomics, genomics, epigenomics) are integrated to perform interference correction and effect complementation. This data synthesis significantly improves the recognition accuracy of low-dose benzene exposure (up to 89%) and enables predictive modeling, ultimately facilitating individualized risk stratification, targeted interventions, and enhanced disease prevention. Tt-MA, trans, trans-muconic acid; SPMA, S-phenylmercapturic acid.

traditional reactive monitoring strategies, heavily reliant on late-stage hematological indices and low-specificity markers such as urinary phenol, are inadequate for chronic low-dose exposure scenarios (245-248).

The present review underscores a necessary paradigm shift. The integration of high-specificity exposure markers (SPMA), advanced effect markers (exhaled breath metabolomics) and susceptibility profiling (*GSTM1/CYP2E1* polymorphisms)

provides a robust foundation for early warning systems. Notably, the pronounced ethnicity disparities in genetic susceptibility dictate that a 'one-size-fits-all' regulatory approach is no longer tenable; future OELs must be re-evaluated through the lens of population-specific genetic vulnerability. Moving forward, bridging the gap between molecular insights and occupational health applications requires overcoming logistical barriers—such as the cost and field-stability of multi-omics tools—and harnessing AI-driven analytics to manage complex biomarker datasets. By transitioning to proactive, individualized and multi-dimensional biomarker frameworks, occupational health authorities can achieve precision risk stratification, ultimately mitigating the global burden of benzene-induced malignancies and systemic diseases.

Acknowledgements

The authors would like to acknowledge Professor Dr Li Sheng and Mr. Li Wang from Chongqing Medical and Pharmaceutical College (Chongqing, China) for their invaluable contributions to the data collection process; their meticulous efforts ensured the accuracy and reliability of the research findings.

Funding

The authors declare that financial support was received for the research, authorship and publication of this article. The present work was funded by the Scientific Research Project of AnShun University, Guizhou Province [grant nos. asxybsjj (202307) and asxykpt (202402)], the Natural Science Research Project of Guizhou Provincial Department of Education (grant no. Qian Jiao He KY [2020] No. 063), the Guizhou Provincial Department of Education (grant no. Qian Ke He KY [2013] No. 130), the Guizhou Provincial Department of Science and Technology (grant no. Qian Ke He LH [2015] No. 7687), the 2023 Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau) (grant no. 2023GGXM006), the Joint Project of Chongqing Health Commission and Science and Technology Bureau (Joint Key Laboratory Open Project) (grant no. 2026KFXM051), the Chongqing Municipal Education Commission Youth Project (grant nos. KJQN202402821 and KJQN202502819), the Natural Science Foundation of Chongqing (grant no. CSTB2025NSCO-GPX1116), the 2026 Key Project of Special Scientific Research of First Affiliated Hospital of Chongqing Medical and Pharmaceutical College (grant no. YGZZKFS2026104) and The Key Laboratory Project of Chongqing Medical and Pharmaceutical College (grant no. YGZPT2025101).

Availability of data and materials

Not applicable.

Authors' contributions

YH, ZX, JM and XL contributed to the writing of the original draft and the preparation of figures. YH contributed to the systematic literature search, data extraction, and synthesis of the reviewed studies. JM and XL reviewed and edited the

manuscript, and provided supervision. All authors read and approved the final version of the manuscript. Data authentication not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chen Y, Wang J, Zhang W, Guo X, Ren J, Zhang L and Gao A: Extracellular vesicles-derived long noncoding RNAs participated in benzene hematotoxicity by mediating apoptosis and autophagy. *Toxicol Appl Pharmacol* 491: 117076, 2024.
2. Elkama A, Ilik N, Senturk K and Karahalil B: Biomonitoring cytogenetic and oxidative-stress related damage in gas station attendants: Buccal micronucleus cytome assay and serum 8-OHdG levels. *Arch Environ Occup Health* 80: 165-173, 2025.
3. Elkama A, Senturk K and Karahalil B: Assessment of genotoxicity biomarkers in gasoline station attendants due to occupational exposure. *Toxicol Ind Health* 40: 337-351, 2024.
4. Giardini I, da Poca KS, da Silva PVB, Andrade Silva VJC, Cintra DS, Friedrich K, Geraldino BR, Otero UB and Sarpa M: Hematological changes in gas station workers. *Int J Environ Res Public Health* 20: 5896, 2023.
5. Guedes Pinto T, Dias TA, Renno ACM, de Barros Viana M and Ribeiro DA: The role of genetic polymorphisms for inducing genotoxicity in workers occupationally exposed to benzene: A systematic review. *Arch Toxicol* 98: 1991-2005, 2024.
6. Guo Y, Deng X, Dai K, Deng M, He J, Si H, Xu X, Niu Z, Wang C, Yao W and Hao C: Benchmark dose estimation based on oxidative damage in Chinese workers exposed to benzene series compounds. *Environ Toxicol Pharmacol* 100: 104150, 2023.
7. Landskroner EA and Tsai CS: Occupational exposures and cancer risk in commercial laundry and dry cleaning industries: A scoping review. *BMC Public Health* 23: 2561, 2023.
8. Li H, Sun Q, Li F, Wang B and Zhu B: Metabolomics of benzene exposure and development of biomarkers for exposure hazard assessment. *Metabolites* 14: 377, 2024.
9. Lima S, Santiago F, Silvestre RT, Elexias SRV, Ornellas MH and Carvalho MMR: Recent advances in biomonitoring of gas station workers: A systematic review. *Asian Pac J Cancer Prev* 25: 3439-3445, 2024.
10. Lv Y, Li Z, Chen Y, Qin F, Liao Q, Zhang Z, Deng Q, Liu Q, Long Z, Wang Q, *et al*: miR-451a and miR-486-5p: Biomarkers for benzene-induced hematotoxicity. *Arch Toxicol* 99: 717-728, 2025.
11. Moghadasi A, Yousefinejad S and Soleimani E: False positives and false negatives in benzene biological monitoring. *Environ Res* 243: 117836, 2024.
12. Moro AM, Brucker N, Goethel G, Flesch I, Nascimento S, Charao M, Gauer B, Sauer E, Cestonaro LV, Vicozzi GP, *et al*: The influence of blood titanium levels on DNA damage in Brazilian workers occupationally exposed to different chemical agents. *Biol Trace Elem Res* 203: 4013-4026, 2025.
13. Anigilaje EA, Nasir ZA and Walton C: Exposure to benzene, toluene, ethylbenzene, and xylene (BTEX) at Nigeria's petrol stations: A review of current status, challenges and future directions. *Front Public Health* 12: 1295758, 2024.
14. Bassig BA, Shu XO, Friesen MC, Vermeulen R, Purdue MP, Ji BT, Yang G, Wong JYY, Appel N, Hu W, *et al*: Occupational exposure to benzene and risk of non-Hodgkin lymphoma in an extended follow-up of two population-based prospective cohorts of Chinese men and women. *Int J Cancer* 155: 2159-2168, 2024.

15. Bove FJ, Greek A, Gatiba R, Boehm RC and Mohnsen MM: Evaluation of mortality among Marines, Navy personnel, and civilian workers exposed to contaminated drinking water at USMC base Camp Lejeune: A cohort study. *Environ Health* 23: 61, 2024.
16. Cao Y, Wang T, Xi J, Tian W, Liu W, Sun Y, Liu W, You X, Li A, Zhang G, *et al*: Benchmark dose estimation for benzene-exposed workers in China: Based on quantitative and multi-endpoint genotoxicity assessments. *Environ Pollut* 330: 121765, 2023.
17. Chaiklieng S: Risk assessment of workers' exposure to BTEX and hazardous area classification at gasoline stations. *PLoS One* 16: e0249913, 2021.
18. Chaiklieng S, Tongsantia U, Suggaravetsiri P and Autrup H: Assessment of exposure to benzene among gasoline station workers in Thailand: Risk assessment matrix methods. *Int J Environ Res Public Health* 22: 397, 2025.
19. Chakr N and Sav A: The role of personal protective equipment (PPE) in reducing firefighter exposure to chemical hazards: A systematic review. *J Occup Environ Hyg* 21: 831-841, 2024.
20. Chuang YS, Lee CY, Lin PC, Pan CH, Hsieh HM, Wu CF and Wu MT: Breast cancer incidence in a national cohort of female workers exposed to special health hazards in Taiwan: A retrospective case-cohort study of ~300,000 occupational records spanning 20 years. *Int Arch Occup Environ Health* 95: 1979-1993, 2022.
21. Das A, Giri BS and Manjunatha R: Systematic review on benzene, toluene, ethylbenzene, and xylene (BTEX) emissions; health impact assessment; and detection techniques in oil and natural gas operations. *Environ Sci Pollut Res Int* 32: 1-22, 2025.
22. De Maria L, Ledda C, Caputi A, Mansi F, Cannone ESS, Sponselli S, Cavone D, Birtolo F, Cannizzaro E, Ferri GM, *et al*: Biological Monitoring of Exposure to Benzene in Port Workers. *Front Public Health* 8: 271, 2020.
23. Fan DY, Wu Y, Gu ZC and Yi JP: Analysis on occupational health monitoring to workers in Zhoushan City. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 38: 944-947, 2020 (In Chinese).
24. Ferla LG, da-Rocha GHO, de-Oliveira RTD and Barioni ED: Risk perception of automotive fuel poisoning among gas station attendants. *Rev Bras Med Trab* 20: 422-429, 2023.
25. Gaikwad AS, Mahmood R, Beerappa R, Karunamoorthy P and Venugopal D: Mitochondrial DNA copy number and cytogenetic damage among fuel filling station attendants. *Environ Mol Mutagen* 61: 820-829, 2020.
26. Ge C, Spoerri A, Egger M, Rothman N, Lan Q, Huss A and Vermeulen R: Swiss National Cohort: Occupational exposure to benzene and mortality risk of lymphohaematopoietic cancers in the Swiss National Cohort. *Scand J Work Environ Health* 50: 351-358, 2024.
27. Lee JH, Gatera VA, Smith T, Panimbang F, Gonzalez A, Abdulah R, Bonham C, Bryant AK and Liu S: Biomonitoring of exposures to solvents and metals in electronics manufacturing facilities in Batam, Indonesia. *New Solut* 33: 220-235, 2024.
28. Li P, Li ML, Gao Y and Wang X: Analysis on the detection of suspected occupational diseases and occupational contraindications for benzene workers in Tianjin. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 40: 283-287, 2022 (In Chinese).
29. Li P, Wang X, Zeng Q, Ren J, Qin RN and Zhang JY: Interaction analysis of the influence of different factors and benzene exposure on workers' alanine aminotransferase. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 41: 831-835, 2023 (In Chinese).
30. Li X, Wang D, Liu A, Hu W and Sun X: Epidemiological characteristics of occupational cancers reported - China, 2006-2020. *China CDC Wkly* 4: 370-373, 2022.
31. Linet MS, Gilbert ES, Vermeulen R, Dores GM, Yin SN, Portengen L, Hayes RB, Ji BT, Lan Q, Li GL and Rothman N: Benzene exposure-response and risk of lymphoid neoplasms in Chinese workers: A multicenter case-cohort study. *Am J Ind Med* 63: 741-754, 2020.
32. Lu Y, Zhang Z, Yan H, Rui B and Liu J: Effects of occupational hazards on job stress and mental health of factory workers and miners: A propensity score analysis. *Biomed Res Int* 2020: 1754897, 2020.
33. Maher T, Kong N, Spray R, Lee S, Gurgel S, Waks J, Kramer DB, Ellenbogen KA, Zimetbaum P and d'Avila A: Safety and behavior of implantable electronic devices during cremation. *Heart Rhythm* 22: 1073-1079, 2025.
34. Markowska M, Krajewski A, Maciejewska D, Jelen H, Kaczmarek M and Stachowska E: Qualitative analysis of surgical smoke produced during burn operations. *Burns* 46: 1356-1364, 2020.
35. Men JL, Men JY, Zhang YJ, Zhao L, Zhang J, Zhang ZH, Zhang D, Shao H and Lu QY: Investigation on occupational hazards in 20 automobile manufacturing enterprises in Shandong Province. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 39: 198-202, 2021 (In Chinese).
36. Navarro KM, Fent K, Mayer AC, Brueck SE, Toennis C, Law B, Meadows J, Sammons D and Brown S: Characterization of inhalation exposures at a wildfire incident during the Wildland Firefighter Exposure and Health Effects (WFFEHE) Study. *Ann Work Expo Health* 67: 1011-1017, 2023.
37. Rong X, Guo JY and Wang Z: Results analysis of occupational physical examination for major occupational hazards exposed laborer in 2018 in Guangzhou. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 38: 37-41, 2020 (In Chinese).
38. Samsel K, Navaneelan T, DeBono N, Everest L, Demers PA and Sritharan J: Leukemia Incidence by Occupation and Industry: A cohort study of 2.3 million workers from ontario, Canada. *Int J Environ Res Public Health* 21: 981, 2024.
39. Tehrani AM, Hajiketabi S, Berijani N and Samadi M: Investigating the respiratory and systemic effects of exposure to BTEX among municipal solid waste workers. *Environ Pollut* 366: 125525, 2025.
40. Verma N, Pandit S, Gupta PK, Kumar S, Kumar A, Giri SK, Yadav G and Priya K: Occupational health hazards and wide spectrum of genetic damage by the organic solvent fumes at the workplace: A critical appraisal. *Environ Sci Pollut Res Int* 29: 30954-30966, 2022.
41. Wang B, Xu S, Sun Q, Li X, Wang T, Xu K, Yin L, Sun R, Pu Y and Zhang J: Let-7e-5p, a promising novel biomarker for benzene toxicity, is involved in benzene-induced hematopoietic toxicity through targeting caspase-3 and p21. *Ecotoxicol Environ Saf* 246: 114142, 2022.
42. Wang H, Feng D, He Y, Jin X and Fu S: Comprehensive interventions to reduce occupational hazards among medical staff in the pathology department of five primary hospitals. *BMC Public Health* 23: 2136, 2023.
43. Wang J, Ma Y, Tang L, Li D, Xie J, Sun Y and Tian Y: Long-term exposure to low concentrations of ambient benzene and mortality in a national english cohort. *Am J Respir Crit Care Med* 209: 987-994, 2024.
44. Wang LH, Zhu ZL, Dai ZT, Feng J and Weng SF: Analysis of volatile organic components of organic solvents used in Bao'an District of Shenzhen. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 40: 867-871, 2022 (In Chinese).
45. Wang T, Cao Y, Xia Z, Christiani DC and Au WW: Review on novel toxicological effects and personalized health hazard in workers exposed to low doses of benzene. *Arch Toxicol* 98: 365-374, 2024.
46. Yan L, Liu Y, Zhang J, Chen X, Li J and Zhu X: In vivo and in vitro study of the potential hazards of surgical smoke during cervical cancer treatment with an ultrasonic scalpel. *Gynecol Oncol* 164: 587-595, 2022.
47. Zhang L, Sun P, Sun D, Zhou Y, Han L, Zhang H, Zhu B and Wang B: Occupational health risk assessment of the benzene exposure industries: A comprehensive scoring method through 4 health risk assessment models. *Environ Sci Pollut Res Int* 29: 84300-84311, 2022.
48. Zhang Z, Shi W, Ru L and Lv W: Biomarkers of occupational benzene exposure: A Systematic Review to estimate the exposure levels and individual susceptibility at low doses. *Toxicol Ind Health* 40: 539-555, 2024.
49. Zhou L, Wei F, Fang X, Zhang Y, Hu Y, Lou X, Xue P and Zou H: Epidemiological characteristics of occupational chemical poisonings in Zhejiang, China from 2006 to 2020: A descriptive analysis. *Front Public Health* 10: 999677, 2022.
50. Tramontana M, Hansel K, Bianchi L, Sensini C, Malatesta N and Stingeni L: Advancing the understanding of allergic contact dermatitis: From pathophysiology to novel therapeutic approaches. *Front Med (Lausanne)* 10: 1184289, 2023.
51. de Groot A, van Oers EM, Ipenburg NA and Rustemeyer T: Allergic contact dermatitis caused by glucose sensors and insulin pumps: A full review: Part 2. Case reports and case series, clinical features, patch test procedures, differentiation from irritant dermatitis, management of allergic patients and (proposed) legislation. *Contact Dermatitis* 92: 164-175, 2025.

52. Qu Z, Jiang Q, Wang B, Yao C, Jiang R, Chen K, Zhou Y, Chen L and Hu F: A cross-sectional study of clinical characteristics and risk factors for hand eczema in the general Chinese population. *Sci Rep* 14: 29733, 2024.
53. Thawabteh AM, Jibreen A, Karaman D, Thawabteh A and Karaman R: Skin pigmentation types, causes and treatment-a review. *Molecules* 28: 4839, 2023.
54. MacGibeny MA, Adjei S, Pyle H, Bunick CG, Ghannoum M, Grada A, Harris-Tryon T, Tying SK and Kong HH: The skin microbiome in dermatologic disease. *J Am Acad Dermatol* 93: 339-348, 2025.
55. Poli D, Mozzoni P, Pinelli S, Cavallo D, Papaleo B and Caporossi L: Sex Difference and benzene exposure: Does it matter? *Int J Environ Res Public Health* 19: 2339, 2022.
56. Lei T, Yang Y and Yang WX: Luteinizing hormone regulates testosterone production, leydig cell proliferation, differentiation, and circadian rhythm during spermatogenesis. *Int J Mol Sci* 26: 3548, 2025.
57. DeMoulin D, Cai H, Vermeulen R, Zheng W, Lipworth L and Shu XO: Occupational benzene exposure and cancer risk among Chinese Men: A report from the Shanghai Men's health study. *Cancer Epidemiol Biomarkers Prev* 33: 1465-1474, 2024.
58. Boitrelle F, Shah R, Saleh R, Henkel R, Kandil H, Chung E, Vogiatzi P, Zini A, Arafa M and Agarwal A: Reply to Pallotti *et al*: Comment on 'Boitrelle *et al*. The Sixth Edition of the WHO manual for human semen analysis: A critical review and SWOT analysis. *Life* 2021, 11, 1368'. *Life (Basel)* 12: 1046, 2022.
59. He J, Peng C, Yang X, Li P, Bai J, Jia Q and Bo C: Identification of critical genes associated with oxidative stress pathways in benzene-induced hematotoxicity. *Heliyon* 10: e35427, 2024.
60. Hammer KC, Veiga A and Mahalingaiah S: Environmental toxicant exposure and menstrual cycle length. *Curr Opin Endocrinol Diabetes Obes* 27: 373-379, 2020.
61. Zhang M, Zhang M, Zeng Q, Lin D and Zhang N: Association of p-phenylenediamine exposure with alterations of pulmonary function, pruritus and health-related quality of life in hair dye factory workers: A cross-sectional study. *Sci Rep* 13: 2623, 2023.
62. Mathiesen L, Buerki-Thurnherr T, Pastuschek J, Aengenheister L and Knudsen LE: Fetal exposure to environmental chemicals; insights from placental perfusion studies. *Placenta* 106: 58-66, 2021.
63. Meng LC, Lin CW, Chuang HM, Chen LK and Hsiao FY: Benzodiazepine use during pregnancy and risk of miscarriage. *JAMA Psychiatry* 81: 366-373, 2024.
64. Chiavarini M, Rosignoli P, Sorbara B, Giacchetta I and Fabiani R: Benzene exposure and lung cancer risk: A systematic review and meta-analysis of human studies. *Int J Environ Res Public Health* 21: 205, 2024.
65. Liu Y and Wang J: Benzene exposure increases the risk of non-Hodgkin's lymphoma: A systematic review and meta-analysis of observational studies. *Transl Cancer Res* 11: 1750-1761, 2022.
66. Zhou J, Sui P, Zhao J, Cheng X, Yu T, Cui S, Song X and Xing C: Benzene-induced hematotoxicity enhances the self-renewal ability of HSPCs in Mll-Af9 mice. *Toxicology* 511: 154061, 2025.
67. Zhang Y, Zhou J, Zhao J, Cheng X and Xing C: Chronic benzene exposure impairs the self-renewal capacity of HSPCs in C57BL/6 mice. *Toxicol Res (Camb)* 14: tfaf021, 2025.
68. Ye Z, Huang Q, Wu H, Wang S, Li B, Zeng M, Jiang T, Ye B, Wei Y, Sun L, *et al*: LncRNA SNHG15 sponges miR-3143/FOXO3 to regulate autophagy in ovarian dysfunction induced by benzene exposure. *Toxicol Lett* 412: 152-161, 2025.
69. Yang X, Dong S, Xing C, Li C, Bo C, Meng X, Liu Z, Shao H, Li M and Jia Q: Ferroptosis is involved in the benzene-induced hematotoxicity via mitochondrial ROS-ferritinophagy pathway. *Environ Pollut* 376: 126379, 2025.
70. Vivarelli S, Sevim C, Giambo F and Fenga C: Integrated computational analysis reveals early genetic and epigenetic AML susceptibility biomarkers in benzene-exposed workers. *Int J Mol Sci* 26: 1138, 2025.
71. Kurd N, Afkhami A and Ganji H: Hollow polymer nanospheres (HPSs) as reusable adsorbent for solid-phase extraction (SPE) of trans, trans-muconic acid from urine samples. *J Chromatogr B Analyt Technol Biomed Life Sci* 1263: 124674, 2025.
72. D'Andrea MA, Garg N, Trehan S and Reddy GK: Cardiac abnormalities induced by benzene exposure from the flaring disaster at the BP refinery plant in Texas City. *Int J Occup Med Environ Health* 38: 249-263, 2025.
73. Cull ME, Brown LTL, Grant PM, Xue L and Winn LM: In utero benzene exposure in CD-1 mice results in increased fetal and placental size at gestational day 19, which is dependent upon intra-litter variables. *Reprod Toxicol* 136: 108979, 2025.
74. Zhang L, Liu Z, Zhang W, Wang J, Kang H, Jing J, Han L and Gao A: Gut microbiota-palmitoleic acid-interleukin-5 axis orchestrates benzene-induced hematopoietic toxicity. *Gut Microbes* 16: 2323227, 2024.
75. Xu K, Ji S, Huang J, Yin L, Zhang J, Sun R and Pu Y: ZMAT3 participated in benzene-caused disruption in self-renewal and differentiation of hematopoietic stem cells via TNF- α /NF- β B pathway. *Food Chem Toxicol* 190: 114838, 2024.
76. Xu F, Wang B, Hu J, Cai N, Han L, Jiang M, Zhao Y and Zhu B: Optimization of benzene exposure risk assessment: An integrated approach utilizing internal and external concentrations with a focus on biomarkers S-PMA & t, t-MA. *Sci Total Environ* 926: 171719, 2024.
77. Wu C, Yu X, Li X, An R, Li S, Liu X, Hu X, Li S, Zhou Q, Li L, *et al*: Aberrant METTL14 gene expression contributes to malignant transformation of benzene-exposed myeloid cells. *Ecotoxicol Environ Saf* 276: 116302, 2024.
78. Wang J, Han L, Liu Z, Zhang W, Zhang L, Jing J and Gao A: Targeting IGF2BP1 alleviated benzene hematotoxicity by reprogramming BCAA metabolism and fatty acid oxidation. *Chem Biol Interact* 398: 111107, 2024.
79. Wang F, Ye L, Jiang X, Zhang R, Chen S, Chen L, Yu H, Zeng X, Li D, Xing X, *et al*: Specific CpG sites methylation is associated with hematotoxicity in low-dose benzene-exposed workers. *Environ Int* 186: 108645, 2024.
80. Wang B, Li F, Hu J, Sun F, Han L, Zhang J and Zhu B: UBE2L3 promotes benzene-induced hematotoxicity via autophagy-dependent ferroptosis. *Ecotoxicol Environ Saf* 283: 116773, 2024.
81. Konieczny KA, Paul I, Rodriguez JA and Garcia-Garibay MA: From beam damage to massive reaction amplification under the electron microscope: An ionization-induced chain reaction in crystals of a dewan benzene. *ACS Cent Sci* 10: 2346-2352, 2024.
82. Kim SH, Yu SY, Choo JH, Kim JK, Kim J, Ahn K and Hwang SY: Changes in gene expression related to atopic dermatitis in mothers and infants following VOC exposure. *Int J Mol Sci* 25: 12827, 2024.
83. Jiang M, Cai N, Hu J, Han L, Xu F, Zhu B and Wang B: Genomic and algorithm-based predictive risk assessment models for benzene exposure. *Front Public Health* 12: 1419361, 2025.
84. Jin K, Zhu F, Wu B, Li M, Wang X, Cheng X, Li M, Huang D and Xing C: Leukemia risk assessment of exposure to low-levels of benzene based on the linearized multistage model. *Front Public Health* 12: 1355739, 2024.
85. Gou L, Ma X, Huang L, Qiu M, Guo R, Jia J, Xu P and Lian N: The characteristics of chronic benzene poisoning in 176 Chinese occupational population cases. *Front Public Health* 12: 1498114, 2025.
86. Zhang L, Kang H, Zhang W, Wang J, Liu Z, Jing J, Han L and Gao A: Probiotics ameliorate benzene-induced systemic inflammation and hematopoietic toxicity by inhibiting Bacteroidaceae-mediated ferroptosis. *Sci Total Environ* 899: 165678, 2023.
87. Zhang H, Jiang F, Ling X, Zhong B, Han Y, Pan Z, Yuan Q, Meng J, Zheng D, Chen X, *et al*: PARP-1 inhibits DNMT1-mediated promoter methylation and promotes linc01132 expression in benzene-exposed workers and hydroquinone-induced malignant transformed cells. *Toxicol Mech Methods* 33: 646-655, 2023.
88. Xin Y, Wang B, Zhang H, Han L, Zhou P, Ding X and Zhu B: Machine learning assessment of white blood cell counts in workers exposed to benzene: A historical cohort study. *Environ Sci Pollut Res Int* 30: 38202-38211, 2023.
89. Wang Q, Liu LP, Zhu K, Wang ZH, Zhang M and Bu N: Investigation and analysis of occupational hazard factors in different industries in Tongliao City. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 41: 659-663, 2023 (In Chinese).
90. Wang J, Han L, Liu Z, Zhang W, Zhang L, Jing J and Gao A: Genus unclassified_Muribaculaceae and microbiota-derived butyrate and indole-3-propionic acid are involved in benzene-induced hematopoietic injury in mice. *Chemosphere* 313: 137499, 2023.
91. Zhou B, Wu Q, Fan S, Su Z, Lu C, Peng J, Zhang N, Jin L, Yu D and Zhang J: Mediating effect of oxidative stress on blood pressure elevation in workers exposed to low concentrations of benzene, toluene, and xylene (BTX). *Sci Rep* 14: 26139, 2024.

92. Zheng Z, Li H, Zhang Z, Zhai X and Qin H: Study on the underlying molecular mechanism of benzene-induced nervous system damage in mice based on tandem mass tag (TMT) proteomics. *Toxicol Res (Camb)* 13: tfae036, 2024.
93. Zheng L, Li J, Hu S, Xu L, Luo Z and Deng B: An electrochemiluminescence sensor based on the antenna effect of lanthanide bimetallic-organic framework and europium(III) electrocatalyst as a co-reactant accelerator for sensitive detection of serum amyloid A. *Talanta* 297 (Pt B): 128699, 2026.
94. Zhao H, Li H, Zheng J, Yan H, Lu J, Liu H, Hao H, Dou J, Li Y and Wang S: Cd-MOF and Its Ln(3+)-Post modification products: regulation of luminescence properties and improved detection of uric acid, quinine, and quinidine. *Inorg Chem* 63: 1962-1973, 2024.
95. Zhang W, Chen T, Fu B, Chen H, Fu X and Xing Z: Hyperoxia caused intestinal metabolism disorder in mice. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 35: 980-983, 2023 (In Chinese).
96. Zhang Q, Lu F, Zhang C, Yu X, Yang X and Yan H: Blocking exosomal secretion aggravated 1,4-benzoquinone-induced cytotoxicity. *Environ Toxicol* 39: 1099-1106, 2024.
97. Zhang D, Zhang Y, Xia S, Shen P and Yang C: Metabolic profiling of synovial fluid in human temporomandibular joint osteoarthritis. *Front Immunol* 15: 1335181, 2024.
98. Yu Y, Zhang B, Jiang X, Cui Y, Luo H, Stergiadis S and Wang B: Exploring the metabolomic landscape: *Perilla frutescens* as a promising enhancer of production, flavor, and nutrition in Tan lamb meat. *Meat Sci* 209: 109419, 2024.
99. Ye J, Chen H, Wang Y, Chen H, Huang J, Yang Y, Feng Z and Li W: A preliminary metabolomics study of the database for biological samples of schizophrenia among Chinese ethnic minorities. *BMC Psychiatry* 24: 262, 2024.
100. Yang Z, Li X, Fu Y, Song Y, Simpson CD, Naeher LP, Lin Y and Du D: Mesoporous Pd@Pt nanoparticle label/lateral flow immunoassay integrated with a 3D-printed smartphone reader for detection of wood smoke biomarkers. *ACS Appl Mater Interfaces* 17: 28523-28531, 2025.
101. Yang Y, Zhou G, Ding Y, Shi W, Chen Y, Ge C, Xu B and Yang L: Microbiota dynamics and metabolic mechanisms in fermented sausages inoculated with *Lactiplantibacillus plantarum* and *Staphylococcus xylosus*. *Food Res Int* 201: 115680, 2025.
102. Yu L, Wang B, Liu W, Xu T, Yang M, Wang X, Tan Q, Yang S, Fan L, Cheng M, *et al.*: Cross-sectional and longitudinal associations of styrene and ethylbenzene exposure with heart rate variability alternation among urban adult population in China. *Sci Total Environ* 845: 157231, 2022.
103. Yu L, Sun R, Xu K, Pu Y, Huang J, Liu M, Chen M, Zhang J, Yin L and Pu Y: Lipidomic analysis reveals disturbances in glycerophospholipid and sphingolipid metabolic pathways in benzene-exposed mice. *Toxicol Res (Camb)* 10: 706-718, 2021.
104. You W, Li HY, Ye LZ, Xing XM, Xiao YM, Chen W and Chen LP: Screening of biomarkers in exhaled breath of mice exposed to benzene. *Zhonghua Yu Fang Yi Xue Za Zhi* 55: 672-678, 2021 (In Chinese).
105. Yang Z, Guo C, Li Q, Zhong Y, Ma S, Zhou J, Li X, Huang R and Yu Y: Human health risks estimations from polycyclic aromatic hydrocarbons in serum and their hydroxylated metabolites in paired urine samples. *Environ Pollut* 290: 117975, 2021.
106. Yan M, Zhu H, Luo H, Zhang T, Sun H and Kannan K: Daily exposure to environmental volatile organic compounds triggers oxidative damage: Evidence from a large-scale survey in China. *Environ Sci Technol* 57: 20501-20509, 2023.
107. Yan M, Cheng Z, Zou Q, Zhao H, Yang L, Zhu H, Zhang T and Sun H: Human exposure levels of volatile organic compounds in e-waste recycling area: Get insight into impacts of manipulation mode and associations with oxidative stress markers. *Environ Health (Wash)* 1: 405-415, 2023.
108. Xu Y, Dai C and Xu Z: Sensitive fluorescence turn-on sensing of hydroxyl radical and glucose based on the oxidative degradation of reductive organic cage. *Talanta* 286: 127518, 2025.
109. Xing Z, Zhang R, Zhao Z, Wang L, Yuan L, Yu H, Yang Y, Yang Y, Liu S and Pei C: Identification of four novel flavonoid adducts in *Arabidopsis thaliana* (L.) exposed to isobutyl S-2-diethylaminoethyl methylphosphonothiolate as potential plant exposure biomarkers. *RSC Adv* 12: 35026-35031, 2022.
110. Xie Z, Chen JY, Gao H, Keith RJ, Bhatnagar A, Lorkiewicz P and Srivastava S: Global profiling of urinary mercapturic acids using integrated library-guided analysis. *Environ Sci Technol* 57: 10563-10573, 2023.
111. Xie X, Wang Y, Wen B, Tian J, Cheng Z, Tang S, Nie Y, Wu X, Guo X and Li B: Characterization and metabolism pathway of volatile compounds in blueberries of different varieties and origins analyzed via HS-GC-IMS and HS-SPME-GC-MS. *Food Chem* 480: 143813, 2025.
112. Willey JB, Liang CL, Pollock T, Khoury C, Thomson EM, Walker M and St-Amand A: Cumulative Health Risk from Exposure Load (CHREL): Looking at multi-chemical exposures through the lens of biomonitoring guidance values. *Toxicol Lett* 401: 139-149, 2024.
113. Werder EJ, Beier JJ, Sandler DP, Falkner KC, Gripshover T, Wahlang B, Engel LS and Cave MC: Blood BTEXS and heavy metal levels are associated with liver injury and systemic inflammation in Gulf states residents. *Food Chem Toxicol* 139: 111242, 2020.
114. Wang T, Tang C, He H, Cao Z, Xiao M, He M, Qi J, Li Y and Li X: Evaluation of *Cordyceps sinensis* quality in 15 production areas using metabolomics and the membership function method. *J Fungi (Basel)* 10: 356, 2024.
115. Wang Q, Hou J, Yuan J, Wu Y, Liu W, Luo Y and Christie P: Evaluation of fatty acid derivatives in the remediation of aged PAH-contaminated soil and microbial community and degradation gene response. *Chemosphere* 248: 125983, 2020.
116. Wang J, Guo X, Chen Y, Zhang W, Ren J and Gao A: The m6A reader IGF2BP1 attenuates the stability of RPL36 and cell proliferation to mediate benzene hematotoxicity by recognizing m6A modification. *Toxicology* 503: 153758, 2024.
117. Wang J, Guo X, Chen Y, Zhang W, Ren J and Gao A: Association between benzene exposure, serum levels of cytokines and hematological measures in Chinese workers: A cross-sectional study. *Ecotoxicol Environ Saf* 207: 111562, 2021.
118. Wang DP, Cai DY, Yang XL, Lu X, Lin DF, Li PM, Zhang ZM, Zhang YF and Zhang W: Study of methylation of mitochondrial MT-COI of benzene poisoning. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 38: 664-668, 2020 (In Chinese).
119. Wang B, Han L, Wang K, Zhou Y, Pu Y, Zhang J and Zhu B: Gender differences in hematotoxicity of benzene-exposed workers, three cross-sectional studies on 218,061 subjects. *Environ Sci Pollut Res Int* 28: 57297-57307, 2021.
120. Tiwald C, Spindler V, Scherer M, Pluym N, Peschel O, Leibold E and Scherer G: Investigations on human biomonitoring for assessing the exposure to synthetic rose oxide in the general population. *J Chromatogr B Analyt Technol Biomed Life Sci* 1260: 124629, 2025.
121. Soumane M, Lahlou H and Fazouan N: Insights into the adsorption mechanisms of VOCs molecules on non-oxidized and oxidized SnO(2) (110) monolayer: DFT analysis. *J Mol Model* 31: 58, 2025.
122. Lundberg R, Dahlen J and Lundberg T: Considerations regarding the selection, sampling, extraction, analysis, and modelling of biomarkers in exhaled breath for early lung cancer screening. *J Pharm Biomed Anal* 260: 116787, 2025.
123. Li W, Liu X, Lei N, Liu L, Li X, Ren H, Yin J, Zhang L, Yu T and Fan L: Zinc(II) organic framework based bifunctional biomarker sensor for efficient detection of urinary 5-Hydroxyindoleacetic acid and serum 3-Nitrotyrosine. *Spectrochim Acta A Mol Biomol Spectrosc* 329: 125610, 2025.
124. Li L, Li G, Xie H and Zhang Z: Simultaneous separation and detection of common chiral and achiral metabolites in the urine of human exposed to benzene series by LC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci* 1251: 124428, 2025.
125. Khan A, Allemailem KS, Alradhi AE and Azam F: Preclinical and molecular docking insights into the chemopreventive role of fenugreek seed extract in a murine model of colorectal cancer. *Pharmaceuticals (Basel)* 18: 490, 2025.
126. Hamoud B, Alfaiakwi M, Aljalalmah H, Almael F, Alsaedi S, Saleh K, Ahmad B and Alqaderi H: Association between blood benzene levels and periodontal disease in a nationally representative adult U.S. population. *Int J Environ Res Public Health* 22: 853, 2025.
127. Hammond D, Reid JL, Goniewicz ML, McNeill A, O'Connor RJ, Corsetti D, Brose LS, Schurr B and Robson D: Biomarkers of toxicant exposure among Youth in Canada, England, and the United States Who vape and/or smoke tobacco or do Neither. *Cancer Epidemiol Biomarkers Prev* 34: 815-824, 2025.
128. Fu Y, Song Y, Yang Z, Ruan X, Lin Y and Du D: Rapid and sensitive detection of wood smoke exposure biomarkers using europium fluorescent nanoparticle label/lateral flow immunoassay. *Talanta* 291: 127760, 2025.

129. Feary J, Yu Y, Kabir T, Schofield S, Bevan A, Askinyte V, Honan K, Emirali L, Rubbi A, Willis AE, *et al*: Assessment of cancer biomarkers in the Grenfell firefighter cohort study. *Sci Rep* 15: 15784, 2025.
130. Dai R, Duan Z, Han B, Peng Y, Zhu L, Shen Y and Meng Q: Untargeted metabolomic analysis using UPLC-MS/MS reveals metabolic changes associated with *lanmaoa asiatica* poisoning. *Food Sci Nutr* 13: e70583, 2025.
131. Cho BJ and Kim SR: Associations between indoor air pollution and urinary volatile organic compound biomarkers in Korean adults. *Toxics* 13: 692, 2025.
132. Chen LZ, Wang YR, Zhao ZZ, Zhao SL, Min CC and Xin YN: Intestinal depletion of TM6SF2 exacerbates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through the gut-liver axis. *J Clin Transl Hepatol* 13: 443-455, 2025.
133. Chambers DM, Roberson BJ, Woodruff CA, Blount BC and Bhandari D: Improving volatile organic compound exposure assessment using biomonitoring by relating exposure biomarker levels in blood and urine. *Chem Res Toxicol* 38: 471-477, 2025.
134. Bai S, Qian Z, Chen Y, Liu S, Wang F and Liu F: Traceability of otomatide and its analogs in biological samples using 'specific' metabolites. *Anal Methods* 17: 7207-7216, 2025.
135. Badeenezhad A, Abbasi F, Moazamfard M, Yousefinejad S, Sabaghan M, Veisi A, Parseh I, Azadbakht O and Mohammadpour A: Evaluation of synergistic factors on BTEX urinary biomarkers in motorcycle riders exposed to heavy traffic in a megacity. *Sci Rep* 15: 31576, 2025.
136. Babalola AA, Da-Silva OF, Adelowo AR, Adedara IA and Farombi EO: Diphenyl diselenide mitigates renal and thyroid dysfunction associated with doxorubicin administration in wistar rats. *J Biochem Mol Toxicol* 39: e70431, 2025.
137. Vangravs R, Mezmale L, Slefarska-Wolak D, Dausse E, Ager C, Convalan AH, Fernandez EA, Mayhew CA, Leja M and Mochalski P: Volatilomic signatures of different strains of *Helicobacter pylori*. *Helicobacter* 29: e13064, 2024.
138. Sun H, Huang T, Alam MM, Li J, Jang DW, Wang T, Chen H, Ho YP and Gao Z: Minimizing contact resistance and flicker noise in micro graphene hall sensors using persistent carbene modified gold electrodes. *ACS Appl Mater Interfaces* 16: 31473-31479, 2024.
139. Sonkar R, Ma H and Waxman DJ: Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression. *Toxicol Sci* 200: 324-345, 2024.
140. Shcherban IV, Fedotova VS, Matukhno AE, Shepelev IE, Shcherban OG and Lysenko LV: A method for detecting spatio-temporal patterns of cancer biomarkers-evoked activity using radial basis function network extracted time-domain features from calcium imaging data. *J Neurosci Methods* 405: 110097, 2024.
141. Polyong CP, Roytrakul S, Sirivarasai J, Yingratanasuk T and Thetkathuek A: Novel serum proteomes expressed from benzene exposure among gasoline station attendants. *Biomark Insights* 19: 11772719241259604, 2024.
142. Panigrahi P, Pal Y, Pal Kaur S, Vovusha H, Bae H, Nazir S, Lee H, Panigrahi A and Hussain T: Rapid detection of explicit volatile organic compounds for early diagnosis of lung cancer using MoSi(2)N(4) monolayer. *Chem Asian J* 19: e202400956, 2024.
143. Mathakala V, Ullakula T and Palempalli UMD: Seagrass as a potential nutraceutical to decrease pro-inflammatory markers. *BMC Complement Med Ther* 24: 260, 2024.
144. Lu M, Wang X, Sun N, Huang S, Yang L and Li D: Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to distinguish between spinal muscular atrophy type II and III. *CNS Neurosci Ther* 30: e14718, 2024.
145. Liu H and Luo X: Au- and Pd-Doped SnS(2) monolayers for lung cancer biomarkers (C(3)H(6)O, C(6)H(6), and C(5)H(8)) detection: A density functional theory investigation. *ACS Omega* 9: 7658-7667, 2024.
146. Li S, Liao X, Ma R, Deng N, Wu H, Zhang Z, Chen L, Wang Q, Liao Q, Li Q, *et al*: Effects of Co-exposure to benzene, toluene, and xylene, polymorphisms of microRNA genes, and their interactions on genetic damage in Chinese petrochemical workers. *Toxics* 12: 821, 2024.
147. Kononova E, Mezmale L, Polaka I, Veliks V, Anarkulova L, Vilkoite I, Tolmanis I, Lescinska AM, Stonans I, Pcolkins A, *et al*: Breath fingerprint of colorectal cancer patients based on the gas chromatography-mass spectrometry analysis. *Int J Mol Sci* 25: 1632, 2024.
148. Jin YS, Yi ZC, Zhang YJ, Rong L and Yu CH: Proteomics Study of benzene metabolite hydroquinone induced hematotoxicity in K562 cells. *Biomed Environ Sci* 37: 341-353, 2024.
149. Gashimova E, Temerdashev A, Perunov D, Porkhanov V, Polyakov I, Podzhivotov A and Dmitrieva E: Quantification of cancer biomarkers in urine using volatilomic approach. *Heliyon* 10: e39028, 2024.
150. Gameli PS, Huestis MA, Balloni A, Busardo FP and Carlier J: Metabolism and detection of designer benzodiazepines: A systematic review. *Drug Metab Rev* 56: 359-384, 2024.
151. Gadhoumi H, Dhoulafi Z, Yeddes W, Serairi Beji R, Miled K, Trifi M, Chirchi A, Saidani Tounsi M and Hayouni EA: Biochemical composition, antioxidant capacity and protective effects of three fermented plants beverages on hepatotoxicity and nephrotoxicity induced by carbon tetrachloride in Mice. *Indian J Microbiol* 64: 229-243, 2024.
152. Di Gilio A, Palmisani J, Nisi M, Pizzillo V, Fiorentino M, Rotella S, Mastrofilippo N, Gesualdo L and de Gennaro G: Breath analysis: Identification of potential volatile biomarkers for non-invasive diagnosis of chronic kidney disease (CKD). *Molecules* 29: 4686, 2024.
153. Christensen GM, Marcus M, Naude PJW, Vanker A, Eick SM, Caudle WM, Malcolm-Smith S, Suglia SF, Chang HH, Zar HJ, *et al*: Joint effects of prenatal exposure to indoor air pollution and psychosocial factors on early life inflammation. *Environ Res* 252 (Pt 1): 118822, 2024.
154. Chen Q, Deng Q, Liu Y, Long Z, Li S, Liu Q, Lv Y, Qin J, Yang A, Huang Y, *et al*: Co-exposure of petrochemical workers to noise and mixture of benzene, toluene, ethylbenzene, xylene, and styrene: Impact on mild renal impairment and interaction. *Environ Pollut* 346: 123628, 2024.
155. Boyd B, Choudhuri D and Bobbitt NS: Ab initio molecular dynamics investigation of water and butanone adsorption on UiO-66 with defects. *Langmuir* 40: 23654-23672, 2024.
156. Anand A, Castiglia E and Zamora ML: The association between personal air pollution exposures and fractional exhaled nitric oxide (FeNO): A systematic review. *Curr Environ Health Rep* 11: 210-224, 2024.
157. Alfalasi W, Hussain T and Tit N: Ab initio investigation of functionalization of titanium carbide Ti(3)C(2) MXenes to tune the selective detection of lung cancer biomarkers. *Sci Rep* 14: 1403, 2024.
158. Vaezzadeh V, Zhong G and Zhang G: Benzene polycarboxylic acids as molecular markers of black carbon: Progresses and challenges. *Chemosphere* 341: 140112, 2023.
159. Tian L, Chang Z, Ren Z, Chen Q, Wu M, Pan B and Xing B: Embedding of biochar in soil mineral fractions: Evidence from benzene polycarboxylic acids molecular biomarkers. *Sci Total Environ* 856 (Pt 1): 159025, 2023.
160. Siddique MH, Bukhari S, Khan IU, Essa A, Ali Z, Sabir U, Ayoub O, Saadia H, Yaseen M, Sultan A, *et al*: In silico, in vitro, and in vivo evaluation of caffeine-coated nanoparticles as a promising therapeutic avenue for AML through NF-Kappa B and TRAIL pathways modulation. *Pharmaceuticals (Basel)* 16: 1742, 2023.
161. Scherer G, Pluym N and Scherer M: Comparison of urinary mercapturic acid excretions in users of various tobacco/nicotine products. *Drug Test Anal* 15: 1107-1126, 2023.
162. Sayed AEH, Idriss SK, Abdel-Ghaffar SK and Hussein AAA: Haemato-biochemical, mutagenic, and histopathological changes in *Oreochromis niloticus* exposed to BTX. *Environ Sci Pollut Res Int* 30: 59301-59315, 2023.
163. Santos MVC, Feltrin AS, Costa-Amaral IC, Teixeira LR, Perini JA, Martins DC Jr and Larentis AL: Network analysis of biomarkers associated with occupational exposure to benzene and malathion. *Int J Mol Sci* 24: 9415, 2023.
164. Riccio G, Berenguer CV, Perestrelo R, Pereira F, Berenguer P, Ornelas CP, Sousa AC, Vital JA, Pinto MDC, Pereira JAM, *et al*: Differences in the Volatilomic Urinary Biosignature of Prostate Cancer Patients as a Feasibility Study for the Detection of Potential Biomarkers. *Curr Oncol* 30: 4904-4921, 2023.
165. Rahimpour R, Jalilian H, Mohammadi H and Rahmani A: Biological exposure indices of occupational exposure to benzene: A systematic review. *Heliyon* 9: e21576, 2023.
166. Permatasari HK, Permatasari QI, Taslim NA, Subali D, Kurniawan R, Surya R, Qhabibi FR, Tanner MJ, Batubara SC, Mayulu N, *et al*: Revealing edible bird nest as novel functional foods in combating metabolic syndrome: Comprehensive in silico, in vitro, and in vivo studies. *Nutrients* 15: 3886, 2023.

167. Mozzoni P, Poli D, Pinelli S, Tagliaferri S, Corradi M, Cavallo D, Ursini CL and Pignini D: Benzene exposure and MicroRNAs expression: In vitro, in vivo and human findings. *Int J Environ Res Public Health* 20: 1920, 2023.
168. Milos T, Rojo D, Nedic Erjavec G, Konjevod M, Tudor L, Vuic B, Svob Strac D, Uzun S, Mimica N, Kozumplik O, *et al*: Metabolic profiling of Alzheimer's disease: Untargeted metabolomics analysis of plasma samples. *Prog Neuropsychopharmacol Biol Psychiatry* 127: 110830, 2023.
169. Luo R, Xu CG, Zhang DM, Wang LL, Wu RX, Chen GB, Lu P, Fan YH and Shao F: Stable Co(II)-based coordination polymer as fluorescence sensor for the discriminative sensing of biomarker methylmalonic acid. *Talanta* 265: 124803, 2023.
170. LaPorte MG, Alvarez C, Chatterley A, Kovaliov M, Carder EJ, Houghton MJ, Lim C, Miller ER, Samankumara LP, Liang M, *et al*: Optimization of 1,2,4-Triazole-Based p97 inhibitors for the treatment of cancer. *ACS Med Chem Lett* 14: 977-985, 2023.
171. Kulka M, Wagner A, Cho JY, Alam SB, Santos JR, Jovel J, Karamchand L and Marcet-Palacios M: Agarose/crystalline nanocellulose (CNC) composites promote bone marrow-derived mast cell integrity, degranulation and receptor expression but inhibit production of de novo synthesized mediators. *Front Bioeng Biotechnol* 11: 1160460, 2023.
172. Jimenez-Garza O, Ghosh M, Barrow TM and Godderis L: Toxicomethylomics revisited: A state-of-the-science review about DNA methylation modifications in blood cells from workers exposed to toxic agents. *Front Public Health* 11: 1073658, 2023.
173. Ibeto C, Onyekachi O and Aju E: Environmental and health risks assessment of n-alkanes and BTEX in Eze Iyi River at oil spill site in Isuikwuato, Abia State, Nigeria. *Environ Monit Assess* 195: 717, 2023.
174. Huang X, Li Z, Zhang T, Zhu J, Wang X, Nie M, Harada K, Zhang J and Zou X: Research progress in human biological monitoring of aromatic hydrocarbon with emphasis on the analytical technology of biomarkers. *Ecotoxicol Environ Saf* 257: 114917, 2023.
175. Hoseini M, Samaei MR, Shahesmaeili A, Martinez SS and Amiri H: Using biomonitoring as a complementary approach in BTEX exposure assessment in the general population and occupational settings: A systematic review and meta-analysis. *Rev Environ Health* 38: 493-510, 2022.
176. Hayama-Terada M, Aochi Y, Ikehara S, Kimura T, Yamagishi K, Sato T and Iso H: Paternal occupational exposures and infant congenital heart defects in the Japan Environment and Children's Study. *Environ Health Prev Med* 28: 12, 2023.
177. Hiler M, Weidner AS, Hull LC, Kurti AN and Mishina EV: Systemic biomarkers of exposure associated with ENDS use: a scoping review. *Tob Control* 32: 480-488, 2023.
178. Gies H, Lupker M, Galy V, Hemingway J, Boehman B, Schwab M, Haghipour N and Eglinton TI: Multi-molecular (14)C evidence for mineral control on terrestrial carbon storage and export. *Philos Trans A Math Phys Eng Sci* 381: 20220328, 2023.
179. Felton TW, Ahmed W, White IR, van Oort P, Rattray NJW, Docherty C, Bannard-Smith J, Morton B, Welters I, McMullan R, *et al*: Analysis of exhaled breath to identify critically ill patients with ventilator-associated pneumonia. *Anaesthesia* 78: 712-721, 2023.
180. Ekozin A, Adeyemi CN and Otuechere CA: Commelina benghalensis (Wandering Jew) Linn exhibits abortifacient potentials and hepatotoxicity in pregnant Wistar rats via elevating indicators of oxidative stress and activating proinflammatory cytokines. *J Ethnopharmacol* 301: 115803, 2023.
181. Dai K, Wang C, Yao W and Hao C: Expression level and function analysis of serum miRNAs in workers with occupational exposure to benzene series. *Chemosphere* 313: 137460, 2023.
182. Ram US, Pogue JA, Soike M, Pfister NJ, Jacob R and Cardenas C: Assessing quantitative performance and expert review of multiple deep learning-based frameworks for computed tomography-based abdominal organ auto-segmentation. *Intell Oncol* 1: 160-171, 2025.
183. Chen M, Carmella SG, Lindgren BR, Luo X, Ikuemonisan J, Niesen B, Thomson NM, Murphy SE, Hatsukami DK and Hecht SS: Increased levels of the acrolein metabolite 3-hydroxypropyl mercapturic acid in the urine of e-cigarette users. *Chem Res Toxicol* 36: 583-588, 2023.
184. Bowman BA, Lewis EV, Goldy DW, Kim JY, Elio DM, Blount BC and Bhandari D: Assessment of urinary 6-hydroxy-2,4-cyclohexadienyl mercapturic acid as a novel biomarker of benzene exposure. *J Anal Toxicol* 47: 597-605, 2023.
185. Boniardi L, Campo L, Olgiati L, Longhi F, Scuffi C and Fustinoni S: Biological monitoring and personal exposure to traffic-related air pollutants of elementary school-age children living in a metropolitan area. *Sci Total Environ* 857 (Pt 3): 159654, 2023.
186. Blatt-Janmaat K, Neumann S, Schmidt F, Ziegler J, Qu Y and Peters K: Impact of in vitro phytohormone treatments on the metabolome of the leafy liverwort *Radula complanata* (L.) Dumort. *Metabolomics* 19: 17, 2023.
187. Bhandari D, Zhu Y, Zhang C, Zhu W, Alexandridis A, Etemadi A, Freedman ND, Chang C, Abnet CC, Dawsey SM, *et al*: Smoke exposure associated with higher urinary benzene biomarker muconic acid (MUCA) in Golestan Cohort Study participants. *Biomarkers* 28: 637-642, 2023.
188. Barakat H, Alkabeer IA, Althwab SA, Alfheaid HA, Alhomaaid RM, Almujaydil MS, Almuziree RSA, Bushnaq T and Mohamed A: Nephroprotective effect of fennel (*Foeniculum vulgare*) seeds and their sprouts on CCl(4)-Induced nephrotoxicity and oxidative stress in rats. *Antioxidants (Basel)* 12: 325, 2023.
189. Hardi H, Barinda AJ, Mahata LE and Fitrianti Z: CYP2C19 variability and clinical outcomes of clopidogrel, proton pump inhibitors, and voriconazole in Southeast Asia: A systematic review and meta-analysis. *Front Pharmacol* 16: 1572886, 2025.
190. van der Laan L, Cardenas A, Vermeulen R, Fadadu RP, Hubbard AE, Phillips RV, Zhang L, Breeze C, Hu W, Wen C, *et al*: Epigenetic aging biomarkers and occupational exposure to benzene, trichloroethylene and formaldehyde. *Environ Int* 158: 106871, 2022.
191. Thetkathuek A, Pattama Polyong C, Jaidee W and Sirivarasai J: Comparison of urinary biomarkers concentrations in exposed and non-exposed petrol station workers in the Eastern Economic Corridor (EEC), Thailand. *Rocz Panstw Zakl Hig* 73: 109-119, 2022.
192. Taunk K, Porto-Figueira P, Pereira JAM, Taware R, da Costa NL, Barbosa R, Rapole S and Camara JS: Urinary volatome expression pattern: Paving the way for identification of potential candidate biosignatures for lung cancer. *Metabolites* 12: 36, 2022.
193. Sun Q, Wang B, Xu S, Cong X, Pu Y and Zhang J: Research development and trends of benzene-induced leukemia from 1990 to 2019-A bibliometric analysis. *Environ Sci Pollut Res Int* 29: 9626-9639, 2022.
194. Shin SS, Yang EH, Lee HC, Moon SH and Ryoo JH: Association of metabolites of benzene and toluene with lipid profiles in Korean adults: Korean National Environmental Health Survey (2015-2017). *BMC Public Health* 22: 1917, 2022.
195. Scholten B, Portengen L, Pronk A, Stierum R, Downward GS, Vlaanderen J and Vermeulen R: Estimation of the exposure-response relation between benzene and acute myeloid leukemia by combining epidemiologic, human biomarker, and animal data. *Cancer Epidemiol Biomarkers Prev* 31: 751-757, 2022.
196. Schoeters G, Verheyen VJ, Colles A, Remy S, Martin LR, Govarts E, Nelen V, Den Hond E, De Decker A, Franken C, *et al*: Internal exposure of Flemish teenagers to environmental pollutants: Results of the Flemish environment and health study 2016-2020 (FLEHS IV). *Int J Hyg Environ Health* 242: 113972, 2022.
197. Sana SR, Chen GM, Lv Y, Guo L and Li EY: Metabonomics fingerprint of volatile organic compounds in serum and urine of pregnant women with gestational diabetes mellitus. *World J Diabetes* 13: 888-899, 2022.
198. Riggs DW, Malovichko MV, Gao H, McGraw KE, Taylor BS, Krivokhizhina T, Rai SN, Keith RJ, Bhatnagar A and Srivastava S: Environmental exposure to volatile organic compounds is associated with endothelial injury. *Toxicol Appl Pharmacol* 437: 115877, 2022.
199. Rafiee A, Delgado-Saborit JM, Sly PD, Amiri H and Hoseini M: Exploring urinary biomarkers to assess oxidative DNA damage resulting from BTEX exposure in street children. *Environ Res* 203: 111725, 2022.
200. Qin N, Zhu Y, Zhong Y, Tian J, Li J, Chen L, Fan R and Wei F: External exposure to BTEX, internal biomarker response, and health risk assessment of nonoccupational populations near a coking plant in Southwest China. *Int J Environ Res Public Health* 19: 847, 2022.

201. Puri S, Singh S and Sohal SK: Oviposition behaviour and biochemical response of an insect pest, *Zeugodacus cucurbitae* (Coquillett) (Diptera: Tephritidae) to plant phenolic compound phloroglucinol. *Comp Biochem Physiol C Toxicol Pharmacol* 255: 109291, 2022.
202. Pena A, Aguilera JD, Matatagui D, de la Presa P, Horrillo C, Hernando A and Marin P: Real-time monitoring of breath biomarkers with a magnetoelastic contactless gas sensor: A proof of concept. *Biosensors (Basel)* 12: 871, 2022.
203. Parida PK, Behera BK, Dehury B, Rout AK, Sarkar DJ, Rai A, Das BK and Mohapatra T: Community structure and function of microbiomes in polluted stretches of river Yamuna in New Delhi, India, using shotgun metagenomics. *Environ Sci Pollut Res Int* 29: 71311-71325, 2022.
204. Cui S, Pang B, Yan H, Wu B, Li M, Xing C and Li J: Using urinary biomarkers to estimate the benzene exposure levels in individuals exposed to benzene. *Toxics* 10: 636, 2022.
205. Pal VK, Li AJ, Zhu H and Kannan K: Diurnal variability in urinary volatile organic compound metabolites and its association with oxidative stress biomarkers. *Sci Total Environ* 818: 151704, 2022.
206. Mendes MPR, Paiva MJN, Costa-Amaral IC, Carvalho LVB, Figueiredo VO, Goncalves ES, Larentis AL and Andre LC: Metabolomic study of urine from workers exposed to low concentrations of benzene by UHPLC-ESI-QToF-MS reveals potential biomarkers associated with oxidative stress and genotoxicity. *Metabolites* 12: 978, 2022.
207. Masood N, Alkhadher SAA, Magam SM, Halimoon N, Alsukaibi A, Zakaria MP, Vaezzadeh V, Keshavarzifard M, Maisara S and Khaled Bin Break M: Monitoring of linear alkyl benzenes (LABs) in riverine and estuarine sediments in Malaysia. *Environ Geochem Health* 44: 3687-3702, 2022.
208. Lee I, Park H, Kim MJ, Kim S, Choi S, Park J, Cho YH, Hong S, Yoo J, Cheon GJ, *et al*: Exposure to polycyclic aromatic hydrocarbons and volatile organic compounds is associated with a risk of obesity and diabetes mellitus among Korean adults: Korean National Environmental Health Survey (KoNEHS) 2015-2017. *Int J Hyg Environ Health* 240: 113886, 2022.
209. Kuang H, Feng J, Li Z, Tan J, Zhu W, Lin S, Pang Q, Ye Y and Fan R: Volatile organic compounds from second-hand smoke may increase susceptibility of children through oxidative stress damage. *Environ Res* 207: 112227, 2022.
210. Kohn E, Barchel D, Golik A, Lougassi M, Wainstock T, Berkovitch M and Schwartzburd F: Analysis of 10 urinary BTEX metabolites using LC-MS/MS. *Biomed Chromatogr* 36: e5302, 2022.
211. Kim K, Sung HK, Jang J, Kang CM, Lee K and Park SK: Biological assessment of potential exposure to occupational substances in current semiconductor workers with at least 5 years of employment. *Int J Environ Res Public Health* 19: 8737, 2022.
212. Jafari Roshan S, Mansoori Y, Hosseini SR, Sabour D and Daraei A: Genetic variations in ATM and H2AX loci contribute to risk of hematological abnormalities in individuals exposed to BTEX chemicals. *J Clin Lab Anal* 36: e24321, 2022.
213. Guo X, Zhang L, Wang J, Zhang W, Ren J, Chen Y, Zhang Y and Gao A: Plasma metabolomics study reveals the critical metabolic signatures for benzene-induced hematotoxicity. *JCI Insight* 7: e154999, 2022.
214. Freddi S, Marzuoli C, Pagliara S, Derra G and Sangaletti L: Targeting biomarkers in the gas phase through a chemoresistive electronic nose based on graphene functionalized with metal phthalocyanines. *RSC Adv* 13: 251-263, 2022.
215. Dehghani M, Abbasi A, Taherzadeh Z and Dehghani S: Exposure assessment of wastewater treatment plant employees to BTEX: A biological monitoring approach. *Sci Rep* 12: 21433, 2022.
216. Pancoro A, Karima E, Apriyanto A and Effendi Y: (1)H NMR metabolomics analysis of oil palm stem tissue infected by *Ganoderma boninense* based on field severity indices. *Sci Rep* 12: 21087, 2022.
217. Caron-Beaudoin E, Ayotte P, Aker A, Blanchette C, Ricard S, Gilbert V, Avaré E and Lemire M: Exposure to benzene, toluene and polycyclic aromatic hydrocarbons in Nunavimmiut aged 16 years and over (Nunavik, Canada) - Qanuilirpitaa 2017 survey. *Environ Res* 206: 112586, 2022.
218. Buonauro F, Borra F, Pignini D, Paci E, Spagnoli M, Astolfi ML, Giampaoli O, Sciubba F, Miccheli A, Canepari S, *et al*: Biomonitoring of exposure to urban pollutants and oxidative stress during the COVID-19 lockdown in Rome residents. *Toxics* 10: 267, 2022.
219. Barakat H, Alkabeer IA, Aljutaily T, Almujaaydil MS, Algheshairy RM, Alhomaied RM, Almutairi AS and Mohamed A: Phenolics and volatile compounds of fennel (*Foeniculum vulgare*) seeds and their sprouts prevent oxidative DNA damage and ameliorates CCl₄-induced hepatotoxicity and oxidative stress in rats. *Antioxidants (Basel)* 11: 2318, 2022.
220. Boogaard PJ: Human biomonitoring of low-level benzene exposures. *Crit Rev Toxicol* 52: 799-810, 2022.
221. Arfaenia H, Dobaradaran S, Mahmoodi M, Farjadfar S, Tahmasbiazadeh M and Fazlzadeh M: Urinary profile of PAHs and related compounds in women working in beauty salons. *Sci Total Environ* 851 (Pt 2): 158281, 2022.
222. Allonneau A, Mercier S, Rieunier F, Menguy-Fleuriot A, Louyot C, Duvollet M, Burlaton G, Nicolas A, Jouffroy R and Prunet B: Exposure to fire smoke in fire training structures: A prospective observational study. *Arch Environ Occup Health* 77: 586-597, 2022.
223. Zhu Q, Huang L, Yang Q, Ao Z, Yang R, Krzesniak J, Lou D, Hu L, Dai X, Guo F and Liu F: Metabolomic analysis of exosomal markers in esophageal squamous cell carcinoma. *Nanoscale* 13: 16457-16464, 2021.
224. Zhao J, Wang H, Zhou J, Qian J, Yang H, Zhou Y, Ding H, Gong Y, Qi X, Jiao Y, *et al*: miR-130a-3p, a preclinical therapeutic target for Crohn's disease. *J Crohns Colitis* 15: 647-664, 2021.
225. Zhang YT, Liu Y, Liang HL, Xu QQ, Liu ZH and Weng XG: Metabolomic differences of seminal plasma between boars with high and low average conception rates after artificial insemination. *Reprod Domest Anim* 56: 161-171, 2021.
226. Tevis DS, Willmore A, Bhandari D, Bowman B, Biren C, Kenwood BM, Jacob P, Liu J, Bello K, Hecht SS, *et al*: Large differences in urinary benzene metabolite S-Phenylmercapturic acid quantitation: A comparison of five LC-MS-MS methods. *J Anal Toxicol* 45: 657-665, 2021.
227. Sun R, Xu K, Ji S, Pu Y, Yu L, Yin L, Zhang J and Pu Y: Toxicity in hematopoietic stem cells from bone marrow and peripheral blood in mice after benzene exposure: Single-cell transcriptome sequencing analysis. *Ecotoxicol Environ Saf* 207: 111490, 2021.
228. Smith JW, O'Meally RN, Ng DK, Chen JG, Kensler TW, Cole RN and Groopman JD: Biomonitoring of ambient outdoor air pollutant exposure in humans using targeted serum albumin adductomics. *Chem Res Toxicol* 34: 1183-1196, 2021.
229. Schwedler G, Murawski A, Schmied-Tobies MH, Rucic E, Scherer M, Pluym N, Scherer G, Bethke R and Kolossa-Gehring M: Benzene metabolite SPMA and acrylamide metabolites AAMA and GAMA in urine of children and adolescents in Germany - human biomonitoring results of the German Environmental Survey 2014-2017 (GerES V). *Environ Res* 192: 110295, 2021.
230. Rouget F, Bihannic A, Cordier S, Multigner L, Meyer-Monath M, Mercier F, Pladys P and Garlantezec R: Petroleum and chlorinated solvents in meconium and the risk of hypospadias: A pilot study. *Front Pediatr* 9: 640064, 2021.
231. Rothman N, Vermeulen R, Zhang L, Hu W, Yin S, Rappaport SM, Smith MT, Jones DP, Rahman M, Lan Q and Walker DI: Metabolome-wide association study of occupational exposure to benzene. *Carcinogenesis* 42: 1326-1336, 2021.
232. Rimnacova L, Moos M, Opekar S, Vodrazka P, Pejchal V, Mraz J and Simek P: Ethyl chloroformate mediated gas chromatographic-mass spectrometric biomonitoring of acidic biomarkers of occupational exposure and endogenous metabolites in human urine. *J Chromatogr A* 1656: 462547, 2021.
233. Ramirez-Lopera V, Uribe-Castro D, Bautista-Amorochio H, Silva-Sayago JA, Mateus-Sanchez E, Ardila-Barbosa WY and Perez-Cala TL: The effects of genetic polymorphisms on benzene-exposed workers: A systematic review. *Health Sci Rep* 4: e327, 2021.
234. Pilia I, Campagna M, Marcias G, Fabbri D, Meloni F, Spataro G, Cottica D, Cocheo C, Grignani E, De-Giorgio F, *et al*: Biomarkers of low-level environmental exposure to benzene and oxidative DNA damage in primary school children in Sardinia, Italy. *Int J Environ Res Public Health* 18: 4644, 2021.

235. Napolano F, Corfiati M, Vaira A, Giangaspero G, D'Ongia M, Di Leone G, Trani G, Longo F and Marcuccio P: Campaign of labour inspections on the implementation of protection measures against carcinogenic agents in fuel station workers. *G Ital Med Lav Ergon* 43: 328-333, 2021 (In Italian).
236. Malovichko MV, Abplanalp WT, McFall SA, Taylor BS, Wickramasinghe NS, Sithu ID, Zelko IN, Uchida S, Hill BG, Sutaria SR, *et al*: Subclinical markers of cardiovascular toxicity of benzene inhalation in mice. *Toxicol Appl Pharmacol* 431: 115742, 2021.
237. Lyu J, Li H, Yin D, Zhao M, Sun Q and Guo M: Analysis of eight bile acids in urine of gastric cancer patients based on covalent organic framework enrichment coupled with liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 1653: 462422, 2021.
238. Liu Z, Zhang Y, Meng ZH and Huang CF: Study on the method of detection of benzene exposure biomarkers by solid phase extraction-gas chromatography-tandem mass spectrometry. *Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi* 39: 463-466, 2021 (In Chinese).
239. Yang B, Wei R and Dai J: Deep learning applications in motion management for radiotherapy. *Intell Oncol* 1: 244-255, 2025.
240. Li S, Hu C, Chen C, Zhang J, Bai Y, Tan CS, Ni G, He F, Li W and Ming D: Molybdenum disulfide supported on metal-organic frameworks as an ultrasensitive layer for the electrochemical detection of the ovarian cancer biomarker CA125. *ACS Appl Bio Mater* 4: 5494-5502, 2021.
241. Ledda C: Epidemiological research on occupational and environmental carcinogens. *Int J Environ Res Public Health* 18: 2215, 2021.
242. Kuijpers E, van Wel L, Loh M, Galea KS, Makris KC, Stierum R, Fransman W and Pronk A: A scoping review of technologies and their applicability for exposome-based risk assessment in the oil and gas industry. *Ann Work Expo Health* 65: 1011-1028, 2021.
243. Ji B, Xiao LY, Ren JC, Zhang GH, Wang Y, Dong T, Li J, Zhang F and Xia ZL: Gene-Environment interactions between environmental response genes polymorphisms and mitochondrial DNA copy numbers among benzene workers. *J Occup Environ Med* 63: e408-e415, 2021.
244. Hadei M, Shahsavani A, Hopke PK, Naseri S, Yazdanbakhsh A, Sadani M, Mesdaghinia A, Yarahmadi M, Rahmatinia M, Fallah S, *et al*: A systematic review and meta-analysis of human biomonitoring studies on exposure to environmental pollutants in Iran. *Ecotoxicol Environ Saf* 212: 111986, 2021.
245. Geraldino BR, Nunes RFN, Gomes JB, da Poca KS, Giardini I, Silva PVB, Souza HP, Otero UB and Sarpa M: Evaluation of Exposure to Toluene and Xylene in Gasoline Station Workers. *Adv Prev Med* 2021: 5553633, 2021.
246. Drera G, Freddi S, Emelianov AV, Bobrinetskiy II, Chiesa M, Zanotti M, Pagliara S, Fedorov FS, Nasibulin AG, Montuschi P and Sangaletti L: Exploring the performance of a functionalized CNT-based sensor array for breathomics through clustering and classification algorithms: From gas sensing of selective biomarkers to discrimination of chronic obstructive pulmonary disease. *RSC Adv* 11: 30270-30282, 2021.
247. Dominguez M, Blandez JF, Lozano-Torres B, de la Torre C, Licchelli M, Mangano C, Amendola V, Sancenon F and Martinez-Manez R: A nanoprobe based on gated mesoporous silica nanoparticles for the selective and sensitive detection of benzene metabolite t,t-Muconic acid in urine. *Chemistry* 27: 1306-1310, 2021.
248. Daulton E, Wicaksono AN, Tiele A, Kocher HM, Debernardi S, Crnogorac-Jurcevic T and Covington JA: Volatile organic compounds (VOCs) for the non-invasive detection of pancreatic cancer from urine. *Talanta* 221: 121604, 2021.



Copyright © 2026 Huang et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.